



## ***Modular Program Report***

The following report(s) provides findings from an FDA-initiated query using its Mini-Sentinel pilot. While Mini-Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Mini-Sentinel, and seeking to better understand the capabilities of the Mini-Sentinel pilot.

Data obtained through Mini-Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Mini-Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Mini-Sentinel Operations Center for assistance at [info@mini-sentinel.org](mailto:info@mini-sentinel.org).

**Overview**

**Request Description** FDA requested execution of Modular Program #2 (MP2), version 3.1, to investigate use of several antiepileptic drugs (AEDs): acetazolamide, carbamazepine, clobazam, clonazepam, diazepam, ethosuxamide, ezogabine, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam, lorazepam, oxcarbazepine, phenobarbital, phenytoin, pregabalin, primidone, rufinamide, tiagabine, topiramate, valproic acid, vigabatrin, and zonisamide. This involved one run of MP2. The query was run against the Mini-Sentinel Distributed Database (MSDD) for the time period of January 1, 2004 to December 31, 2012. The request was distributed to 18 Data Partners on April 23, 2012. **This report presents incident use of each AED where incidence is defined with respect to all listed AEDs.** Incidence with respect to the drug of interest only is presented in a separate report.

Results provide counts of prevalent and incident users of the AEDs listed above, new starts (incident use only), dispensings, total days supplied, eligible members, and member-days. Total days supplied are from the Mini-Sentinel Common Data Model (MSCDM) outpatient pharmacy table for records identified using valid NDCs (for oral forms). A new start was defined as a 183-day washout period of no prior use of the specified drug product.

**Request ID** msy4\_mpr28\_v1 - Report 2 of 2

**Table of Contents**

<b><u>Specifications</u></b>	Program parameter inputs and scenarios
<b><u>Glossary</u></b>	List of terms found in this report and their definitions
<b><u>Table 1a</u></b>	Table displaying the number of prevalent AED users, dispensings, total days supplied, eligible members, member-days, new users per 1,000 eligible members, days supplied per user, dispensings per user, and days supplied per dispensing by drug product - January 1, 2004 - December 31, 2012.
<b><u>Table 1b</u></b>	Table displaying the number of incident AED users, new starts, dispensings, total days supplied, eligible members, member-days, new users per 1,000 eligible members, days supplied per user, dispensings per user, and days supplied per dispensing by drug product - January 1, 2004 - December 31, 2012.
<b><u>Table 2a</u></b>	Table displaying the number of prevalent AED users, dispensings, total days supplied, eligible members, member-days, new users per 1,000 eligible members, days supplied per user, dispensings per user, and days supplied per dispensing by drug product and age group - January 1, 2004 - December 31, 2012.
<b><u>Table 2b</u></b>	Table displaying the number of incident AED users, new starts, dispensings, total days supplied, eligible members, member-days, new users per 1,000 eligible members, days supplied per user, dispensings per user, and days supplied per dispensing by drug product and age group - January 1, 2004 - December 31, 2012.
<b><u>Table 3a</u></b>	Table displaying the number of prevalent AED users, dispensings, total days supplied, eligible members, member-days, new users per 1,000 eligible members, days supplied per user, dispensings per user, and days supplied per dispensing by drug product and sex - January 1, 2004 - December 31, 2012.
<b><u>Table 3b</u></b>	Table displaying the number of incident AED users, new starts, dispensings, total days supplied, eligible members, member-days, new users per 1,000 eligible members, days supplied per user, dispensings per user, and days supplied per dispensing by drug product and sex - January 1, 2004 - December 31, 2012.
<b><u>Table 4a</u></b>	Table displaying the number of prevalent AED users, dispensings, total days supplied, eligible members, member-days, new users per 1,000 eligible members, days supplied per user, dispensings per user, and days supplied per dispensing by drug product and year - January 1, 2004 - December 31, 2012.
<b><u>Table 4b</u></b>	Table displaying the number of incident AED users, new starts, dispensings, total days supplied, eligible members, member-days, new users per 1,000 eligible members, days supplied per user, dispensings per user, and days supplied per dispensing by drug product and year - January 1, 2004 - December 31, 2012.
<b>Notes:</b>	Please contact the Mini-Sentinel Operations Center (MSOC_Requests@harvardpilgrim.org) for questions and to provide comments/suggestions for future enhancements to this document.

**MSY4\_MPR28\_V1 Specifications #2**

Modular Program #2, version 3.1, was used to investigate use of several antiepileptic drugs (AEDs). The query period was from January 1, 2004 to December 31, 2012, and the enrollment gap was set at 45 days. Age groups were split as follows: 0-<2, 2-<5, 5-<10, 10-<17, 17-<40, 40-<65, and 65+ years. In total, 25 different scenarios are examined in this request with differing exposures of interest. See below for a description of each of these scenarios.

<b>Drug/Exposure Criteria</b>				
<b>Scenario</b>	<b>Incident exposure</b>	<b>Incident w/ respect to (incidence criteria):</b>	<b>Washout (days)</b>	<b>Incidence Type*</b>
1	Acetazolamide	All listed AEDs	183	MULT
2	Carbamazepine	All listed AEDs	183	MULT
3	Clobazam	All listed AEDs	183	MULT
4	Clonazepam	All listed AEDs	183	MULT
5	Diazepam	All listed AEDs	183	MULT
6	Ethosuxamide	All listed AEDs	183	MULT
7	Ezogabine	All listed AEDs	183	MULT
8	Felbamate	All listed AEDs	183	MULT
9	Gabapentin	All listed AEDs	183	MULT
10	Lacosamide	All listed AEDs	183	MULT
11	Lamotrigine	All listed AEDs	183	MULT
12	Levetiracetam	All listed AEDs	183	MULT
13	Lorazepam	All listed AEDs	183	MULT
14	Mephenytoin	All listed AEDs	183	MULT
15	Oxcarbazepine	All listed AEDs	183	MULT
16	Phenobarbital	All listed AEDs	183	MULT
17	Phenytoin, phenytoin sodium	All listed AEDs	183	MULT
18	Pregabalin	All listed AEDs	183	MULT
19	Primidone	All listed AEDs	183	MULT
20	Rufinamide	All listed AEDs	183	MULT
21	Tiagabine	All listed AEDs	183	MULT
22	Topiramate	All listed AEDs	183	MULT
23	Valproic acid	All listed AEDs	183	MULT
24	Vigabatrin	All listed AEDs	183	MULT
25	Zonisamide	All listed AEDs	183	MULT

\*A "MULT" incidence type for the exposure will consider all incident exposures (dispensings) for a member during the query period.

### Glossary of Terms in Modular Program 2\*

**Eligible Members (incidence-based cohort)** - Number of members eligible for incident exposure (defined by the washout period) with specified coverage during the query period.

**Eligible Members (prevalence-based cohort)** - Number of members with at least one day of specified coverage during the query period.

**Enrollment Gap** - number of days allowed between two consecutive enrollment periods without breaking a “continuously enrolled” sequence.

**Incidence Type (drug/exposure)** - Minimum incidence type will consider the first dispensing in the query period as a new start as long as it is the first dispensing in the user's entire available history. Multiple incidence type will use the washout period to establish incidence, however Multiple will consider all qualifying incident dispensings as new starts.

**Member-Days (incidence-based cohort)** - Sum of all days of enrollment with specified coverage in the query period preceded by an exposure washout period.

**Member-Days (prevalence-based cohort)** - Sum of all days members are enrolled with specified coverage during the query period.

**New Starts**- Number of incident exposures during the query period. User must have no prior exposures in the washout period. For a minimum incidence type, an individual may have no more than one new start. For a multiple incidence type, an individual may have more than one new start.

**New Users** - Number of members with incident exposure during the query period. Member must have no evidence of exposure (s) of interest (defined by incidence criteria) in the prior washout period. A user may only be counted once in a query period.

**Query Period** - Period in which the modular program looks for exposures of interest.

**Washout Period (drug/exposure)** - Number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous specified coverage.

\*all terms may not be used in this report

**Table 1a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product**

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
Acetazolamide	228,974	607,152	16,550,557	121,289,091	105,073,234,753	188.8	72.3	2.7	27.3
Carbamazepine	313,830	3,724,009	139,949,159	121,289,091	105,073,234,753	258.7	445.9	11.9	37.6
Clobazam	691	2,407	78,346	121,289,091	105,073,234,753	0.6	113.4	3.5	32.5
Clonazepam	1,965,809	15,632,574	496,249,684	121,289,091	105,073,234,753	1,620.8	252.4	8.0	31.7
Diazepam	2,908,242	9,946,947	219,092,261	121,289,091	105,073,234,753	2,397.8	75.3	3.4	22.0
Ethosuxamide	8,472	104,818	3,722,767	121,289,091	105,073,234,753	7.0	439.4	12.4	35.5
Ezogabine	58	132	4,057	121,289,091	105,073,234,753	0.0	69.9	2.3	30.7
Felbamate	3,233	59,632	2,072,301	121,289,091	105,073,234,753	2.7	641.0	18.4	34.8
Gabapentin	3,090,205	21,238,425	780,800,914	121,289,091	105,073,234,753	2,547.8	252.7	6.9	36.8
Lacosamide	14,747	107,891	3,529,848	121,289,091	105,073,234,753	12.2	239.4	7.3	32.7
Lamotrigine	726,430	8,003,136	284,699,943	121,289,091	105,073,234,753	598.9	391.9	11.0	35.6
Levetiracetam	343,529	3,436,123	121,242,966	121,289,091	105,073,234,753	283.2	352.9	10.0	35.3
Lorazepam	3,386,329	17,535,138	450,388,602	121,289,091	105,073,234,753	2,791.9	133.0	5.2	25.7
Mephenytoin	1	1	30	121,289,091	105,073,234,753	0.0	30.0	1.0	30.0
Oxcarbazepine	262,237	2,503,564	84,232,724	121,289,091	105,073,234,753	216.2	321.2	9.5	33.6
Phenobarbital	78,234	936,353	34,927,655	121,289,091	105,073,234,753	64.5	446.5	12.0	37.3
Phenytoin, phenytoin sodium	324,143	4,580,272	170,540,569	121,289,091	105,073,234,753	267.2	526.1	14.1	37.2
Pregabalin	799,223	4,888,249	163,423,824	121,289,091	105,073,234,753	658.9	204.5	6.1	33.4
Primidone	108,304	1,171,103	47,163,175	121,289,091	105,073,234,753	89.3	435.5	10.8	40.3
Rufinamide	2,055	19,123	615,530	121,289,091	105,073,234,753	1.7	299.5	9.3	32.2
Tiagabine	38,076	241,581	7,743,690	121,289,091	105,073,234,753	31.4	203.4	6.3	32.1
Topiramate	931,477	7,214,904	254,747,683	121,289,091	105,073,234,753	768.0	273.5	7.7	35.3
Valproic acid	50,363	339,723	13,795,796	121,289,091	105,073,234,753	41.5	273.9	6.7	40.6
Vigabatrin	437	4,046	123,219	121,289,091	105,073,234,753	0.4	282.0	9.3	30.5
Zonisamide	93,285	789,167	27,026,070	121,289,091	105,073,234,753	76.9	289.7	8.5	34.2

**Table 1b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product**

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
Acetazolamide	159,833	175,627	295,413	6,601,216	97,234,705	79,873,215,918	164.4	41.3	1.8	22.3
Carbamazepine	87,062	102,117	526,312	21,390,712	97,234,705	79,873,215,918	89.5	245.7	6.0	40.6
Clobazam	40	40	121	3,893	97,234,705	79,873,215,918	0.0	97.3	3.0	32.2
Clonazepam	914,302	1,098,456	4,807,458	149,342,223	97,234,705	79,873,215,918	940.3	163.3	5.3	31.1
Diazepam	1,917,988	2,269,188	4,475,108	79,837,763	97,234,705	79,873,215,918	1,972.5	41.6	2.3	17.8
Ethosuxamide	2,857	3,191	29,149	1,020,807	97,234,705	79,873,215,918	2.9	357.3	10.2	35.0
Ezogabine	1	1	1	30	97,234,705	79,873,215,918	0.0	30.0	1.0	30.0
Felbamate	174	214	2,324	92,674	97,234,705	79,873,215,918	0.2	532.6	13.4	39.9
Gabapentin	1,625,009	1,864,523	8,034,721	301,838,823	97,234,705	79,873,215,918	1,671.2	185.7	4.9	37.6
Lacosamide	1,312	1,340	6,859	213,288	97,234,705	79,873,215,918	1.3	162.6	5.2	31.1
Lamotrigine	228,330	249,397	1,937,048	69,403,176	97,234,705	79,873,215,918	234.8	304.0	8.5	35.8
Levetiracetam	114,088	121,472	834,370	29,593,405	97,234,705	79,873,215,918	117.3	259.4	7.3	35.5
Lorazepam	2,138,231	2,672,425	7,762,561	178,209,046	97,234,705	79,873,215,918	2,199.0	83.3	3.6	23.0
Mephenytoin	1	1	1	30	97,234,705	79,873,215,918	0.0	30.0	1.0	30.0
Oxcarbazepine	81,635	89,421	587,505	19,494,650	97,234,705	79,873,215,918	84.0	238.8	7.2	33.2
Phenobarbital	21,302	23,670	100,918	3,702,520	97,234,705	79,873,215,918	21.9	173.8	4.7	36.7
Phenytoin, phenytoin sodium	87,561	97,978	637,005	24,945,028	97,234,705	79,873,215,918	90.1	284.9	7.3	39.2
Pregabalin	280,279	300,897	1,261,774	42,282,993	97,234,705	79,873,215,918	288.2	150.9	4.5	33.5
Primidone	40,156	45,720	280,903	12,069,348	97,234,705	79,873,215,918	41.3	300.6	7.0	43.0
Rufinamide	97	99	866	27,815	97,234,705	79,873,215,918	0.1	286.8	8.9	32.1
Tiagabine	9,236	9,729	38,301	1,203,169	97,234,705	79,873,215,918	9.5	130.3	4.1	31.4
Topiramate	394,180	438,454	2,226,037	79,021,361	97,234,705	79,873,215,918	405.4	200.5	5.6	35.5
Valproic acid	21,340	25,596	119,780	5,589,875	97,234,705	79,873,215,918	21.9	261.9	5.6	46.7
Vigabatrin	50	51	433	13,199	97,234,705	79,873,215,918	0.1	264.0	8.7	30.5
Zonisamide	23,094	24,829	124,385	4,213,410	97,234,705	79,873,215,918	23.8	182.4	5.4	33.9

**Table 2a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Age Group**

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Acetazolamide</b>									
0-2 years	138	380	9,978	5,668,911	2,189,289,230	2.4	72.3	2.8	26.3
2-5 years	227	672	17,573	7,214,012	3,636,254,820	3.1	77.4	3.0	26.2
5-10 years	1,158	3,554	95,997	10,305,203	6,396,469,967	11.2	82.9	3.1	27.0
10-17 years	6,537	16,252	413,896	13,615,115	9,624,000,886	48.0	63.3	2.5	25.5
17-40 years	53,852	130,894	3,440,023	46,832,594	31,714,782,644	115.0	63.9	2.4	26.3
40-65 years	98,106	252,522	6,855,826	42,577,937	37,202,795,947	230.4	69.9	2.6	27.1
65+ years	71,841	202,878	5,717,264	14,742,004	14,218,632,910	487.3	79.6	2.8	28.2
<b>Carbamazepine</b>									
0-2 years	646	3,247	107,725	5,668,911	2,189,289,230	11.4	166.8	5.0	33.2
2-5 years	2,053	15,125	509,727	7,214,012	3,636,254,820	28.5	248.3	7.4	33.7
5-10 years	5,977	61,415	2,081,167	10,305,203	6,396,469,967	58.0	348.2	10.3	33.9
10-17 years	13,973	157,591	5,411,251	13,615,115	9,624,000,886	102.6	387.3	11.3	34.3
17-40 years	88,163	933,065	32,853,793	46,832,594	31,714,782,644	188.3	372.6	10.6	35.2
40-65 years	148,709	1,794,761	68,255,053	42,577,937	37,202,795,947	349.3	459.0	12.1	38.0
65+ years	71,899	758,805	30,730,443	14,742,004	14,218,632,910	487.7	427.4	10.6	40.5
<b>Clobazam</b>									
0-2 years	28	87	2,690	5,668,911	2,189,289,230	0.5	96.1	3.1	30.9
2-5 years	90	363	11,281	7,214,012	3,636,254,820	1.2	125.3	4.0	31.1
5-10 years	138	487	15,937	10,305,203	6,396,469,967	1.3	115.5	3.5	32.7
10-17 years	199	689	22,692	13,615,115	9,624,000,886	1.5	114.0	3.5	32.9
17-40 years	189	608	19,533	46,832,594	31,714,782,644	0.4	103.3	3.2	32.1
40-65 years	57	151	5,458	42,577,937	37,202,795,947	0.1	95.8	2.6	36.1
65+ years	9	22	755	14,742,004	14,218,632,910	0.1	83.9	2.4	34.3

**Table 2a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Age Group**

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b><i>Clonazepam</i></b>									
0-2 years	1,285	5,381	156,456	5,668,911	2,189,289,230	22.7	121.8	4.2	29.1
2-5 years	2,503	15,060	450,241	7,214,012	3,636,254,820	34.7	179.9	6.0	29.9
5-10 years	6,274	38,542	1,192,569	10,305,203	6,396,469,967	60.9	190.1	6.1	30.9
10-17 years	27,978	130,558	3,886,361	13,615,115	9,624,000,886	205.5	138.9	4.7	29.8
17-40 years	680,924	3,794,605	106,691,348	46,832,594	31,714,782,644	1,454.0	156.7	5.6	28.1
40-65 years	1,021,937	9,089,306	289,844,844	42,577,937	37,202,795,947	2,400.2	283.6	8.9	31.9
65+ years	292,944	2,559,122	94,027,865	14,742,004	14,218,632,910	1,987.1	321.0	8.7	36.7
<b><i>Diazepam</i></b>									
0-2 years	1,560	3,244	65,020	5,668,911	2,189,289,230	27.5	41.7	2.1	20.0
2-5 years	8,151	14,092	184,304	7,214,012	3,636,254,820	113.0	22.6	1.7	13.1
5-10 years	26,865	44,567	470,117	10,305,203	6,396,469,967	260.7	17.5	1.7	10.5
10-17 years	64,377	98,964	1,072,470	13,615,115	9,624,000,886	472.8	16.7	1.5	10.8
17-40 years	846,816	1,878,631	30,316,352	46,832,594	31,714,782,644	1,808.2	35.8	2.2	16.1
40-65 years	1,551,188	5,906,159	131,375,314	42,577,937	37,202,795,947	3,643.2	84.7	3.8	22.2
65+ years	461,585	2,001,290	55,608,684	14,742,004	14,218,632,910	3,131.1	120.5	4.3	27.8
<b><i>Ethosuxamide</i></b>									
0-2 years	29	115	3,603	5,668,911	2,189,289,230	0.5	124.2	4.0	31.3
2-5 years	640	3,881	122,467	7,214,012	3,636,254,820	8.9	191.4	6.1	31.6
5-10 years	3,677	34,484	1,146,889	10,305,203	6,396,469,967	35.7	311.9	9.4	33.3
10-17 years	3,055	31,148	1,079,432	13,615,115	9,624,000,886	22.4	353.3	10.2	34.7
17-40 years	1,388	15,605	573,229	46,832,594	31,714,782,644	3.0	413.0	11.2	36.7
40-65 years	976	16,713	670,504	42,577,937	37,202,795,947	2.3	687.0	17.1	40.1
65+ years	196	2,872	126,643	14,742,004	14,218,632,910	1.3	646.1	14.7	44.1



**Table 2a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Age Group**

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b><i>Ezogabine</i></b>									
0-2 years	0	0	0	5,668,911	2,189,289,230	0.0	---	---	---
2-5 years	0	0	0	7,214,012	3,636,254,820	0.0	---	---	---
5-10 years	1	1	30	10,305,203	6,396,469,967	0.0	30.0	1.0	30.0
10-17 years	4	7	213	13,615,115	9,624,000,886	0.0	53.3	1.8	30.4
17-40 years	29	60	1,877	46,832,594	31,714,782,644	0.1	64.7	2.1	31.3
40-65 years	22	57	1,727	42,577,937	37,202,795,947	0.1	78.5	2.6	30.3
65+ years	3	7	210	14,742,004	14,218,632,910	0.0	70.0	2.3	30.0
<b><i>Felbamate</i></b>									
0-2 years	73	389	11,221	5,668,911	2,189,289,230	1.3	153.7	5.3	28.8
2-5 years	186	1,737	56,358	7,214,012	3,636,254,820	2.6	303.0	9.3	32.4
5-10 years	423	5,301	175,425	10,305,203	6,396,469,967	4.1	414.7	12.5	33.1
10-17 years	677	10,254	343,012	13,615,115	9,624,000,886	5.0	506.7	15.1	33.5
17-40 years	1,341	25,446	863,580	46,832,594	31,714,782,644	2.9	644.0	19.0	33.9
40-65 years	871	14,589	545,262	42,577,937	37,202,795,947	2.0	626.0	16.7	37.4
65+ years	144	1,916	77,443	14,742,004	14,218,632,910	1.0	537.8	13.3	40.4
<b><i>Gabapentin</i></b>									
0-2 years	345	1,170	35,275	5,668,911	2,189,289,230	6.1	102.2	3.4	30.1
2-5 years	1,244	6,152	184,776	7,214,012	3,636,254,820	17.2	148.5	4.9	30.0
5-10 years	3,930	21,243	669,716	10,305,203	6,396,469,967	38.1	170.4	5.4	31.5
10-17 years	19,807	91,386	2,938,997	13,615,115	9,624,000,886	145.5	148.4	4.6	32.2
17-40 years	455,963	2,020,717	64,302,770	46,832,594	31,714,782,644	973.6	141.0	4.4	31.8
40-65 years	1,574,439	10,532,255	376,881,850	42,577,937	37,202,795,947	3,697.8	239.4	6.7	35.8
65+ years	1,112,836	8,565,502	335,787,530	14,742,004	14,218,632,910	7,548.7	301.7	7.7	39.2

**Table 2a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Age Group**

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b><i>Lacosamide</i></b>									
0-2 years	41	164	5,301	5,668,911	2,189,289,230	0.7	129.3	4.0	32.3
2-5 years	118	612	18,260	7,214,012	3,636,254,820	1.6	154.7	5.2	29.8
5-10 years	348	2,309	74,224	10,305,203	6,396,469,967	3.4	213.3	6.6	32.1
10-17 years	869	6,758	217,339	13,615,115	9,624,000,886	6.4	250.1	7.8	32.2
17-40 years	5,744	42,256	1,361,821	46,832,594	31,714,782,644	12.3	237.1	7.4	32.2
40-65 years	6,445	46,406	1,547,963	42,577,937	37,202,795,947	15.1	240.2	7.2	33.4
65+ years	1,596	9,386	304,940	14,742,004	14,218,632,910	10.8	191.1	5.9	32.5
<b><i>Lamotrigine</i></b>									
0-2 years	482	2,523	80,767	5,668,911	2,189,289,230	8.5	167.6	5.2	32.0
2-5 years	2,551	21,265	698,624	7,214,012	3,636,254,820	35.4	273.9	8.3	32.9
5-10 years	12,077	127,012	4,182,160	10,305,203	6,396,469,967	117.2	346.3	10.5	32.9
10-17 years	50,342	493,306	16,386,800	13,615,115	9,624,000,886	369.8	325.5	9.8	33.2
17-40 years	333,510	3,056,434	103,945,039	46,832,594	31,714,782,644	712.1	311.7	9.2	34.0
40-65 years	319,923	3,757,287	137,997,262	42,577,937	37,202,795,947	751.4	431.3	11.7	36.7
65+ years	48,427	545,309	21,409,291	14,742,004	14,218,632,910	328.5	442.1	11.3	39.3
<b><i>Levetiracetam</i></b>									
0-2 years	5,311	30,927	992,418	5,668,911	2,189,289,230	93.7	186.9	5.8	32.1
2-5 years	8,897	77,149	2,499,345	7,214,012	3,636,254,820	123.3	280.9	8.7	32.4
5-10 years	13,229	139,520	4,584,859	10,305,203	6,396,469,967	128.4	346.6	10.5	32.9
10-17 years	19,680	214,207	7,164,587	13,615,115	9,624,000,886	144.5	364.1	10.9	33.4
17-40 years	84,644	807,223	27,612,338	46,832,594	31,714,782,644	180.7	326.2	9.5	34.2
40-65 years	134,500	1,290,441	46,178,482	42,577,937	37,202,795,947	315.9	343.3	9.6	35.8
65+ years	96,300	876,656	32,210,937	14,742,004	14,218,632,910	653.2	334.5	9.1	36.7

**Table 2a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Age Group**

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Lorazepam</b>									
0-2 years	1,535	2,674	53,029	5,668,911	2,189,289,230	27.1	34.5	1.7	19.8
2-5 years	2,351	4,954	95,137	7,214,012	3,636,254,820	32.6	40.5	2.1	19.2
5-10 years	7,481	15,008	262,801	10,305,203	6,396,469,967	72.6	35.1	2.0	17.5
10-17 years	41,097	84,633	1,477,201	13,615,115	9,624,000,886	301.8	35.9	2.1	17.5
17-40 years	902,618	2,783,303	57,417,336	46,832,594	31,714,782,644	1,927.3	63.6	3.1	20.6
40-65 years	1,698,439	9,279,633	234,065,739	42,577,937	37,202,795,947	3,989.0	137.8	5.5	25.2
65+ years	816,190	5,364,933	157,017,359	14,742,004	14,218,632,910	5,536.5	192.4	6.6	29.3
<b>Mephenytoin</b>									
0-2 years	0	0	0	5,668,911	2,189,289,230	0.0	---	---	---
2-5 years	0	0	0	7,214,012	3,636,254,820	0.0	---	---	---
5-10 years	0	0	0	10,305,203	6,396,469,967	0.0	---	---	---
10-17 years	0	0	0	13,615,115	9,624,000,886	0.0	---	---	---
17-40 years	0	0	0	46,832,594	31,714,782,644	0.0	---	---	---
40-65 years	1	1	30	42,577,937	37,202,795,947	0.0	30.0	1.0	30.0
65+ years	0	0	0	14,742,004	14,218,632,910	0.0	---	---	---
<b>Oxcarbazepine</b>									
0-2 years	1,950	10,019	319,610	5,668,911	2,189,289,230	34.4	163.9	5.1	31.9
2-5 years	5,672	44,544	1,399,812	7,214,012	3,636,254,820	78.6	246.8	7.9	31.4
5-10 years	18,001	173,709	5,455,934	10,305,203	6,396,469,967	174.7	303.1	9.6	31.4
10-17 years	39,828	384,607	12,457,391	13,615,115	9,624,000,886	292.5	312.8	9.7	32.4
17-40 years	95,741	763,818	24,954,022	46,832,594	31,714,782,644	204.4	260.6	8.0	32.7
40-65 years	94,690	894,290	31,095,791	42,577,937	37,202,795,947	222.4	328.4	9.4	34.8
65+ years	25,493	232,577	8,550,164	14,742,004	14,218,632,910	172.9	335.4	9.1	36.8

**Table 2a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Age Group**

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b><i>Phenobarbital</i></b>									
0-2 years	6,600	31,124	969,500	5,668,911	2,189,289,230	116.4	146.9	4.7	31.1
2-5 years	2,307	21,308	692,054	7,214,012	3,636,254,820	32.0	300.0	9.2	32.5
5-10 years	1,729	23,529	767,827	10,305,203	6,396,469,967	16.8	444.1	13.6	32.6
10-17 years	1,992	32,756	1,055,647	13,615,115	9,624,000,886	14.6	529.9	16.4	32.2
17-40 years	13,488	133,167	4,447,457	46,832,594	31,714,782,644	28.8	329.7	9.9	33.4
40-65 years	33,420	463,425	17,399,176	42,577,937	37,202,795,947	78.5	520.6	13.9	37.5
65+ years	23,720	231,044	9,595,994	14,742,004	14,218,632,910	160.9	404.6	9.7	41.5
<b><i>Phenytoin, phenytoin</i></b>									
0-2 years	601	1,774	55,439	5,668,911	2,189,289,230	10.6	92.2	3.0	31.3
2-5 years	856	3,809	118,205	7,214,012	3,636,254,820	11.9	138.1	4.4	31.0
5-10 years	1,513	9,982	324,448	10,305,203	6,396,469,967	14.7	214.4	6.6	32.5
10-17 years	4,080	28,471	957,808	13,615,115	9,624,000,886	30.0	234.8	7.0	33.6
17-40 years	57,587	617,029	21,169,312	46,832,594	31,714,782,644	123.0	367.6	10.7	34.3
40-65 years	153,152	2,242,867	82,727,645	42,577,937	37,202,795,947	359.7	540.2	14.6	36.9
65+ years	121,422	1,676,340	65,187,712	14,742,004	14,218,632,910	823.6	536.9	13.8	38.9
<b><i>Pregabalin</i></b>									
0-2 years	28	177	5,079	5,668,911	2,189,289,230	0.5	181.4	6.3	28.7
2-5 years	125	938	28,512	7,214,012	3,636,254,820	1.7	228.1	7.5	30.4
5-10 years	324	2,332	73,993	10,305,203	6,396,469,967	3.1	228.4	7.2	31.7
10-17 years	2,593	12,348	381,870	13,615,115	9,624,000,886	19.0	147.3	4.8	30.9
17-40 years	115,946	533,973	16,577,798	46,832,594	31,714,782,644	247.6	143.0	4.6	31.0
40-65 years	449,418	2,750,568	92,262,962	42,577,937	37,202,795,947	1,055.5	205.3	6.1	33.5
65+ years	246,459	1,587,913	54,093,610	14,742,004	14,218,632,910	1,671.8	219.5	6.4	34.1

**Table 2a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Age Group**

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Primidone</b>									
0-2 years	21	101	2,719	5,668,911	2,189,289,230	0.4	129.5	4.8	26.9
2-5 years	46	409	13,549	7,214,012	3,636,254,820	0.6	294.5	8.9	33.1
5-10 years	126	1,525	49,279	10,305,203	6,396,469,967	1.2	391.1	12.1	32.3
10-17 years	424	4,321	137,494	13,615,115	9,624,000,886	3.1	324.3	10.2	31.8
17-40 years	5,919	46,789	1,575,912	46,832,594	31,714,782,644	12.6	266.2	7.9	33.7
40-65 years	38,007	396,557	15,147,043	42,577,937	37,202,795,947	89.3	398.5	10.4	38.2
65+ years	67,058	721,401	30,237,179	14,742,004	14,218,632,910	454.9	450.9	10.8	41.9
<b>Rufinamide</b>									
0-2 years	62	189	5,886	5,668,911	2,189,289,230	1.1	94.9	3.0	31.1
2-5 years	260	1,818	57,087	7,214,012	3,636,254,820	3.6	219.6	7.0	31.4
5-10 years	488	3,944	125,012	10,305,203	6,396,469,967	4.7	256.2	8.1	31.7
10-17 years	610	5,311	171,457	13,615,115	9,624,000,886	4.5	281.1	8.7	32.3
17-40 years	663	6,350	207,240	46,832,594	31,714,782,644	1.4	312.6	9.6	32.6
40-65 years	174	1,470	47,386	42,577,937	37,202,795,947	0.4	272.3	8.4	32.2
65+ years	9	41	1,462	14,742,004	14,218,632,910	0.1	162.4	4.6	35.7
<b>Tiagabine</b>									
0-2 years	14	31	820	5,668,911	2,189,289,230	0.2	58.6	2.2	26.5
2-5 years	41	272	8,040	7,214,012	3,636,254,820	0.6	196.1	6.6	29.6
5-10 years	249	1,610	50,232	10,305,203	6,396,469,967	2.4	201.7	6.5	31.2
10-17 years	1,000	7,321	232,694	13,615,115	9,624,000,886	7.3	232.7	7.3	31.8
17-40 years	11,857	62,554	1,929,712	46,832,594	31,714,782,644	25.3	162.7	5.3	30.8
40-65 years	22,530	146,894	4,774,774	42,577,937	37,202,795,947	52.9	211.9	6.5	32.5
65+ years	3,263	22,899	747,418	14,742,004	14,218,632,910	22.1	229.1	7.0	32.6

**Table 2a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Age Group**

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b><i>Topiramate</i></b>									
0-2 years	1,631	10,442	323,160	5,668,911	2,189,289,230	28.8	198.1	6.4	30.9
2-5 years	2,735	22,826	741,288	7,214,012	3,636,254,820	37.9	271.0	8.3	32.5
5-10 years	9,067	69,992	2,266,851	10,305,203	6,396,469,967	88.0	250.0	7.7	32.4
10-17 years	46,045	284,979	9,372,691	13,615,115	9,624,000,886	338.2	203.6	6.2	32.9
17-40 years	386,111	2,421,070	81,146,765	46,832,594	31,714,782,644	824.4	210.2	6.3	33.5
40-65 years	463,368	3,950,907	143,007,820	42,577,937	37,202,795,947	1,088.3	308.6	8.5	36.2
65+ years	60,758	454,688	17,889,108	14,742,004	14,218,632,910	412.1	294.4	7.5	39.3
<b><i>Valproic acid</i></b>									
0-2 years	8	9	270	5,668,911	2,189,289,230	0.1	33.8	1.1	30.0
2-5 years	43	128	4,618	7,214,012	3,636,254,820	0.6	107.4	3.0	36.1
5-10 years	436	1,887	72,329	10,305,203	6,396,469,967	4.2	165.9	4.3	38.3
10-17 years	2,269	9,745	373,106	13,615,115	9,624,000,886	16.7	164.4	4.3	38.3
17-40 years	16,247	73,810	2,794,961	46,832,594	31,714,782,644	34.7	172.0	4.5	37.9
40-65 years	23,201	178,361	7,243,439	42,577,937	37,202,795,947	54.5	312.2	7.7	40.6
65+ years	9,843	75,783	3,307,073	14,742,004	14,218,632,910	66.8	336.0	7.7	43.6
<b><i>Vigabatrin</i></b>									
0-2 years	183	1,082	32,998	5,668,911	2,189,289,230	3.2	180.3	5.9	30.5
2-5 years	127	891	27,309	7,214,012	3,636,254,820	1.8	215.0	7.0	30.6
5-10 years	84	871	26,402	10,305,203	6,396,469,967	0.8	314.3	10.4	30.3
10-17 years	60	571	17,435	13,615,115	9,624,000,886	0.4	290.6	9.5	30.5
17-40 years	50	515	15,419	46,832,594	31,714,782,644	0.1	308.4	10.3	29.9
40-65 years	14	115	3,626	42,577,937	37,202,795,947	0.0	259.0	8.2	31.5
65+ years	1	1	30	14,742,004	14,218,632,910	0.0	30.0	1.0	30.0
<b><i>Zonisamide</i></b>									
0-2 years	641	4,011	124,224	5,668,911	2,189,289,230	11.3	193.8	6.3	31.0
2-5 years	1,304	12,327	384,798	7,214,012	3,636,254,820	18.1	295.1	9.5	31.2
5-10 years	2,609	30,436	992,226	10,305,203	6,396,469,967	25.3	380.3	11.7	32.6
10-17 years	5,810	62,297	2,032,536	13,615,115	9,624,000,886	42.7	349.8	10.7	32.6
17-40 years	33,984	250,393	8,305,086	46,832,594	31,714,782,644	72.6	244.4	7.4	33.2
40-65 years	44,620	354,117	12,292,901	42,577,937	37,202,795,947	104.8	275.5	7.9	34.7
65+ years	8,642	75,586	2,894,299	14,742,004	14,218,632,910	58.6	334.9	8.7	38.3

**Table 2b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Age Group**

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Acetazolamide</b>										
0-2 years	59	60	157	4,027	3,812,846	1,275,911,969	1.5	68.3	2.7	25.6
2-5 years	126	132	305	7,393	5,830,329	2,894,602,738	2.2	58.7	2.4	24.2
5-10 years	733	781	1,691	41,825	8,447,162	5,141,935,333	8.7	57.1	2.3	24.7
10-17 years	4,586	4,942	8,538	189,620	11,288,443	7,777,151,743	40.6	41.3	1.9	22.2
17-40 years	36,686	39,034	63,804	1,420,702	36,166,650	23,421,361,017	101.4	38.7	1.7	22.3
40-65 years	68,964	77,216	120,482	2,610,540	34,311,956	28,444,559,754	201.0	37.9	1.7	21.7
65+ years	49,636	53,462	97,467	2,216,745	12,474,746	10,843,812,617	397.9	44.7	2.0	22.7
<b>Carbamazepine</b>										
0-2 years	244	246	967	34,285	3,812,846	1,275,911,969	6.4	140.5	4.0	35.5
2-5 years	767	792	4,462	159,120	5,830,329	2,894,602,738	13.2	207.5	5.8	35.7
5-10 years	1,845	1,930	13,529	473,099	8,447,162	5,141,935,333	21.8	256.4	7.3	35.0
10-17 years	4,345	4,728	29,414	1,049,161	11,288,443	7,777,151,743	38.5	241.5	6.8	35.7
17-40 years	22,623	25,463	121,715	4,473,826	36,166,650	23,421,361,017	62.6	197.8	5.4	36.8
40-65 years	35,820	41,894	204,129	8,509,334	34,311,956	28,444,559,754	104.4	237.6	5.7	41.7
65+ years	22,253	27,064	124,659	5,557,304	12,474,746	10,843,812,617	178.4	249.7	5.6	44.6
<b>Clobazam</b>										
0-2 years	0	0	0	0	3,812,846	1,275,911,969	0.0	---	---	---
2-5 years	11	11	44	1,385	5,830,329	2,894,602,738	0.2	125.9	4.0	31.5
5-10 years	8	8	34	1,230	8,447,162	5,141,935,333	0.1	153.8	4.3	36.2
10-17 years	11	11	24	744	11,288,443	7,777,151,743	0.1	67.6	2.2	31.0
17-40 years	7	7	14	365	36,166,650	23,421,361,017	0.0	52.1	2.0	26.1
40-65 years	3	3	5	169	34,311,956	28,444,559,754	0.0	56.3	1.7	33.8
65+ years	0	0	0	0	12,474,746	10,843,812,617	0.0	---	---	---

**Table 2b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Age Group**

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b><i>Clonazepam</i></b>										
0-2 years	319	324	878	24,696	3,812,846	1,275,911,969	8.4	77.4	2.8	28.1
2-5 years	685	702	2,214	62,251	5,830,329	2,894,602,738	11.7	90.9	3.2	28.1
5-10 years	2,553	2,658	8,117	235,105	8,447,162	5,141,935,333	30.2	92.1	3.2	29.0
10-17 years	14,738	15,764	46,203	1,315,747	11,288,443	7,777,151,743	130.6	89.3	3.1	28.5
17-40 years	326,538	372,568	1,365,475	36,916,008	36,166,650	23,421,361,017	902.9	113.1	4.2	27.0
40-65 years	441,122	538,723	2,467,277	77,023,086	34,311,956	28,444,559,754	1,285.6	174.6	5.6	31.2
65+ years	137,054	167,717	791,549	29,517,401	12,474,746	10,843,812,617	1,098.7	215.4	5.8	37.3
<b><i>Diazepam</i></b>										
0-2 years	848	858	1,361	23,470	3,812,846	1,275,911,969	22.2	27.7	1.6	17.2
2-5 years	5,865	6,102	7,769	57,567	5,830,329	2,894,602,738	100.6	9.8	1.3	7.4
5-10 years	20,210	21,744	27,091	152,183	8,447,162	5,141,935,333	239.3	7.5	1.3	5.6
10-17 years	50,056	52,450	63,045	420,476	11,288,443	7,777,151,743	443.4	8.4	1.3	6.7
17-40 years	558,686	609,441	975,646	12,273,648	36,166,650	23,421,361,017	1,544.8	22.0	1.7	12.6
40-65 years	1,005,025	1,207,369	2,517,709	44,991,813	34,311,956	28,444,559,754	2,929.1	44.8	2.5	17.9
65+ years	294,824	371,224	821,547	20,252,557	12,474,746	10,843,812,617	2,363.4	68.7	2.8	24.7
<b><i>Ethosuxamide</i></b>										
0-2 years	12	12	46	1,345	3,812,846	1,275,911,969	0.3	112.1	3.8	29.2
2-5 years	316	319	1,754	54,769	5,830,329	2,894,602,738	5.4	173.3	5.6	31.2
5-10 years	1,536	1,614	13,821	466,914	8,447,162	5,141,935,333	18.2	304.0	9.0	33.8
10-17 years	754	838	6,567	230,894	11,288,443	7,777,151,743	6.7	306.2	8.7	35.2
17-40 years	210	263	1,259	52,440	36,166,650	23,421,361,017	0.6	249.7	6.0	41.7
40-65 years	87	116	678	32,834	34,311,956	28,444,559,754	0.3	377.4	7.8	48.4
65+ years	22	29	164	8,395	12,474,746	10,843,812,617	0.2	381.6	7.5	51.2



**Table 2b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Age Group**

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b><i>Ezogabine</i></b>										
0-2 years	0	0	0	0	3,812,846	1,275,911,969	0.0	---	---	---
2-5 years	0	0	0	0	5,830,329	2,894,602,738	0.0	---	---	---
5-10 years	0	0	0	0	8,447,162	5,141,935,333	0.0	---	---	---
10-17 years	0	0	0	0	11,288,443	7,777,151,743	0.0	---	---	---
17-40 years	0	0	0	0	36,166,650	23,421,361,017	0.0	---	---	---
40-65 years	1	1	1	30	34,311,956	28,444,559,754	0.0	30.0	1.0	30.0
65+ years	0	0	0	0	12,474,746	10,843,812,617	0.0	---	---	---
<b><i>Felbamate</i></b>										
0-2 years	4	4	29	870	3,812,846	1,275,911,969	0.1	217.5	7.3	30.0
2-5 years	6	6	34	1,334	5,830,329	2,894,602,738	0.1	222.3	5.7	39.2
5-10 years	15	16	168	5,713	8,447,162	5,141,935,333	0.2	380.9	11.2	34.0
10-17 years	24	24	308	12,051	11,288,443	7,777,151,743	0.2	502.1	12.8	39.1
17-40 years	63	68	883	30,615	36,166,650	23,421,361,017	0.2	486.0	14.0	34.7
40-65 years	54	85	580	29,539	34,311,956	28,444,559,754	0.2	547.0	10.7	50.9
65+ years	10	11	34	1,656	12,474,746	10,843,812,617	0.1	165.6	3.4	48.7
<b><i>Gabapentin</i></b>										
0-2 years	140	141	374	11,048	3,812,846	1,275,911,969	3.7	78.9	2.7	29.5
2-5 years	623	639	2,382	71,140	5,830,329	2,894,602,738	10.7	114.2	3.8	29.9
5-10 years	1,984	2,071	7,671	241,755	8,447,162	5,141,935,333	23.5	121.9	3.9	31.5
10-17 years	11,017	11,538	36,843	1,164,493	11,288,443	7,777,151,743	97.6	105.7	3.3	31.6
17-40 years	227,829	246,244	766,729	24,237,963	36,166,650	23,421,361,017	629.9	106.4	3.4	31.6
40-65 years	786,821	894,510	3,701,671	134,268,069	34,311,956	28,444,559,754	2,293.1	170.6	4.7	36.3
65+ years	606,304	709,380	3,369,106	135,608,214	12,474,746	10,843,812,617	4,860.3	223.7	5.6	40.3

**Table 2b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Age Group**

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b><i>Lacosamide</i></b>										
0-2 years	0	0	0	0	3,812,846	1,275,911,969	0.0	---	---	---
2-5 years	5	5	26	814	5,830,329	2,894,602,738	0.1	162.8	5.2	31.3
5-10 years	14	14	51	1,739	8,447,162	5,141,935,333	0.2	124.2	3.6	34.1
10-17 years	48	48	306	9,332	11,288,443	7,777,151,743	0.4	194.4	6.4	30.5
17-40 years	488	500	2,355	72,505	36,166,650	23,421,361,017	1.3	148.6	4.8	30.8
40-65 years	552	564	2,892	90,903	34,311,956	28,444,559,754	1.6	164.7	5.2	31.4
65+ years	206	209	1,048	32,432	12,474,746	10,843,812,617	1.7	157.4	5.1	30.9
<b><i>Lamotrigine</i></b>										
0-2 years	80	81	298	9,535	3,812,846	1,275,911,969	2.1	119.2	3.7	32.0
2-5 years	618	625	3,592	116,864	5,830,329	2,894,602,738	10.6	189.1	5.8	32.5
5-10 years	4,296	4,444	32,819	1,050,072	8,447,162	5,141,935,333	50.9	244.4	7.6	32.0
10-17 years	22,447	23,518	169,900	5,524,157	11,288,443	7,777,151,743	198.8	246.1	7.6	32.5
17-40 years	109,619	118,635	779,185	26,515,255	36,166,650	23,421,361,017	303.1	241.9	7.1	34.0
40-65 years	81,072	88,808	739,161	28,014,798	34,311,956	28,444,559,754	236.3	345.6	9.1	37.9
65+ years	12,111	13,286	104,521	4,235,423	12,474,746	10,843,812,617	97.1	349.7	8.6	40.5
<b><i>Levetiracetam</i></b>										
0-2 years	1,946	1,971	9,519	307,388	3,812,846	1,275,911,969	51.0	158.0	4.9	32.3
2-5 years	3,247	3,332	23,084	757,943	5,830,329	2,894,602,738	55.7	233.4	7.1	32.8
5-10 years	4,148	4,348	32,953	1,095,012	8,447,162	5,141,935,333	49.1	264.0	7.9	33.2
10-17 years	6,328	6,644	50,694	1,704,580	11,288,443	7,777,151,743	56.1	269.4	8.0	33.6
17-40 years	22,886	24,510	148,537	5,086,377	36,166,650	23,421,361,017	63.3	222.2	6.5	34.2
40-65 years	37,455	39,839	242,967	8,637,751	34,311,956	28,444,559,754	109.2	230.6	6.5	35.6
65+ years	38,673	40,828	277,546	10,262,718	12,474,746	10,843,812,617	310.0	265.4	7.2	37.0

**Table 2b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Age Group**

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Lorazepam</b>										
0-2 years	624	630	930	17,164	3,812,846	1,275,911,969	16.4	27.5	1.5	18.5
2-5 years	1,286	1,337	1,852	27,480	5,830,329	2,894,602,738	22.1	21.4	1.4	14.8
5-10 years	4,774	5,065	7,143	96,433	8,447,162	5,141,935,333	56.5	20.2	1.5	13.5
10-17 years	28,070	30,089	48,063	721,067	11,288,443	7,777,151,743	248.7	25.7	1.7	15.0
17-40 years	565,939	660,777	1,431,544	26,617,504	36,166,650	23,421,361,017	1,564.8	47.0	2.5	18.6
40-65 years	1,045,928	1,329,581	3,890,097	86,267,422	34,311,956	28,444,559,754	3,048.3	82.5	3.7	22.2
65+ years	516,696	644,946	2,245,768	60,581,091	12,474,746	10,843,812,617	4,141.9	117.2	4.3	27.0
<b>Mephenytoin</b>										
0-2 years	0	0	0	0	3,812,846	1,275,911,969	0.0	---	---	---
2-5 years	0	0	0	0	5,830,329	2,894,602,738	0.0	---	---	---
5-10 years	0	0	0	0	8,447,162	5,141,935,333	0.0	---	---	---
10-17 years	0	0	0	0	11,288,443	7,777,151,743	0.0	---	---	---
17-40 years	0	0	0	0	36,166,650	23,421,361,017	0.0	---	---	---
40-65 years	1	1	1	30	34,311,956	28,444,559,754	0.0	30.0	1.0	30.0
65+ years	0	0	0	0	12,474,746	10,843,812,617	0.0	---	---	---
<b>Oxcarbazepine</b>										
0-2 years	609	614	2,748	86,195	3,812,846	1,275,911,969	16.0	141.5	4.5	31.4
2-5 years	1,962	2,006	12,629	401,181	5,830,329	2,894,602,738	33.7	204.5	6.4	31.8
5-10 years	7,479	7,856	59,075	1,868,375	8,447,162	5,141,935,333	88.5	249.8	7.9	31.6
10-17 years	16,591	17,817	123,966	3,929,056	11,288,443	7,777,151,743	147.0	236.8	7.5	31.7
17-40 years	28,265	30,535	154,050	4,940,255	36,166,650	23,421,361,017	78.2	174.8	5.5	32.1
40-65 years	21,430	23,518	137,744	4,849,713	34,311,956	28,444,559,754	62.5	226.3	6.4	35.2
65+ years	6,356	7,075	40,188	1,538,196	12,474,746	10,843,812,617	51.0	242.0	6.3	38.3

**Table 2b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Age Group**

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b><i>Phenobarbital</i></b>										
0-2 years	985	991	4,561	138,790	3,812,846	1,275,911,969	25.8	140.9	4.6	30.4
2-5 years	460	477	2,844	92,253	5,830,329	2,894,602,738	7.9	200.6	6.2	32.4
5-10 years	301	328	2,042	77,118	8,447,162	5,141,935,333	3.6	256.2	6.8	37.8
10-17 years	356	400	2,511	83,939	11,288,443	7,777,151,743	3.2	235.8	7.1	33.4
17-40 years	3,967	4,289	14,685	451,314	36,166,650	23,421,361,017	11.0	113.8	3.7	30.7
40-65 years	6,823	7,728	36,931	1,413,847	34,311,956	28,444,559,754	19.9	207.2	5.4	38.3
65+ years	8,515	9,457	29,485	1,155,390	12,474,746	10,843,812,617	68.3	135.7	3.5	39.2
<b><i>Phenytoin, phenytoin sodium</i></b>										
0-2 years	219	221	456	13,220	3,812,846	1,275,911,969	5.7	60.4	2.1	29.0
2-5 years	360	365	1,026	31,709	5,830,329	2,894,602,738	6.2	88.1	2.9	30.9
5-10 years	571	584	1,905	59,976	8,447,162	5,141,935,333	6.8	105.0	3.3	31.5
10-17 years	1,924	1,982	7,153	230,922	11,288,443	7,777,151,743	17.0	120.0	3.7	32.3
17-40 years	17,127	19,091	99,929	3,496,100	36,166,650	23,421,361,017	47.4	204.1	5.8	35.0
40-65 years	35,804	40,624	260,759	10,068,280	34,311,956	28,444,559,754	104.3	281.2	7.3	38.6
65+ years	32,026	35,111	246,398	10,216,980	12,474,746	10,843,812,617	256.7	319.0	7.7	41.5
<b><i>Pregabalin</i></b>										
0-2 years	7	7	32	960	3,812,846	1,275,911,969	0.2	137.1	4.6	30.0
2-5 years	24	25	96	2,817	5,830,329	2,894,602,738	0.4	117.4	4.0	29.3
5-10 years	71	72	218	6,532	8,447,162	5,141,935,333	0.8	92.0	3.1	30.0
10-17 years	959	989	2,856	83,629	11,288,443	7,777,151,743	8.5	87.2	3.0	29.3
17-40 years	41,914	44,067	149,928	4,555,351	36,166,650	23,421,361,017	115.9	108.7	3.6	30.4
40-65 years	156,251	168,065	703,117	23,555,593	34,311,956	28,444,559,754	455.4	150.8	4.5	33.5
65+ years	81,845	87,672	382,742	13,257,017	12,474,746	10,843,812,617	656.1	162.0	4.7	34.6

**Table 2b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Age Group**

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Primidone</b>										
0-2 years	4	4	8	211	3,812,846	1,275,911,969	0.1	52.8	2.0	26.4
2-5 years	5	5	19	630	5,830,329	2,894,602,738	0.1	126.0	3.8	33.2
5-10 years	28	29	229	7,941	8,447,162	5,141,935,333	0.3	283.6	8.2	34.7
10-17 years	141	149	588	18,958	11,288,443	7,777,151,743	1.2	134.5	4.2	32.2
17-40 years	1,983	2,120	8,697	302,055	36,166,650	23,421,361,017	5.5	152.3	4.4	34.7
40-65 years	11,631	12,925	72,947	2,895,962	34,311,956	28,444,559,754	33.9	249.0	6.3	39.7
65+ years	26,521	30,488	193,388	8,603,041	12,474,746	10,843,812,617	212.6	324.4	7.3	44.5
<b>Rufinamide</b>										
0-2 years	1	1	1	30	3,812,846	1,275,911,969	0.0	30.0	1.0	30.0
2-5 years	14	14	93	3,506	5,830,329	2,894,602,738	0.2	250.4	6.6	37.7
5-10 years	26	26	210	6,416	8,447,162	5,141,935,333	0.3	246.8	8.1	30.6
10-17 years	26	27	199	5,908	11,288,443	7,777,151,743	0.2	227.2	7.7	29.7
17-40 years	23	24	195	6,909	36,166,650	23,421,361,017	0.1	300.4	8.5	35.4
40-65 years	6	6	12	360	34,311,956	28,444,559,754	0.0	60.0	2.0	30.0
65+ years	1	1	6	175	12,474,746	10,843,812,617	0.0	175.0	6.0	29.2
<b>Tiagabine</b>										
0-2 years	2	2	3	43	3,812,846	1,275,911,969	0.1	21.5	1.5	14.3
2-5 years	8	8	13	324	5,830,329	2,894,602,738	0.1	40.5	1.6	24.9
5-10 years	64	66	269	8,331	8,447,162	5,141,935,333	0.8	130.2	4.2	31.0
10-17 years	285	297	1,309	42,638	11,288,443	7,777,151,743	2.5	149.6	4.6	32.6
17-40 years	2,988	3,100	10,659	321,237	36,166,650	23,421,361,017	8.3	107.5	3.6	30.1
40-65 years	5,162	5,474	21,905	694,069	34,311,956	28,444,559,754	15.0	134.5	4.2	31.7
65+ years	744	782	3,355	109,606	12,474,746	10,843,812,617	6.0	147.3	4.5	32.7

**Table 2b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Age Group**

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b><i>Topiramate</i></b>										
0-2 years	314	319	1,856	56,969	3,812,846	1,275,911,969	8.2	181.4	5.9	30.7
2-5 years	468	479	2,232	75,491	5,830,329	2,894,602,738	8.0	161.3	4.8	33.8
5-10 years	3,851	4,035	17,940	583,717	8,447,162	5,141,935,333	45.6	151.6	4.7	32.5
10-17 years	25,408	27,191	112,745	3,700,240	11,288,443	7,777,151,743	225.1	145.6	4.4	32.8
17-40 years	173,364	189,857	837,380	28,129,771	36,166,650	23,421,361,017	479.3	162.3	4.8	33.6
40-65 years	174,066	194,599	1,067,284	39,303,428	34,311,956	28,444,559,754	507.3	225.8	6.1	36.8
65+ years	20,085	21,974	100,763	4,089,297	12,474,746	10,843,812,617	161.0	203.6	5.0	40.6
<b><i>Valproic acid</i></b>										
0-2 years	0	0	0	0	3,812,846	1,275,911,969	0.0	---	---	---
2-5 years	15	15	34	1,203	5,830,329	2,894,602,738	0.3	80.2	2.3	35.4
5-10 years	251	271	1,070	39,937	8,447,162	5,141,935,333	3.0	159.1	4.3	37.3
10-17 years	1,360	1,477	5,067	200,385	11,288,443	7,777,151,743	12.0	147.3	3.7	39.5
17-40 years	7,211	8,120	28,709	1,200,650	36,166,650	23,421,361,017	19.9	166.5	4.0	41.8
40-65 years	8,664	10,808	55,122	2,635,684	34,311,956	28,444,559,754	25.3	304.2	6.4	47.8
65+ years	4,085	4,905	25,486	1,289,970	12,474,746	10,843,812,617	32.7	315.8	6.2	50.6
<b><i>Vigabatrin</i></b>										
0-2 years	30	30	180	5,670	3,812,846	1,275,911,969	0.8	189.0	6.0	31.5
2-5 years	8	8	78	2,238	5,830,329	2,894,602,738	0.1	279.8	9.8	28.7
5-10 years	8	8	69	2,066	8,447,162	5,141,935,333	0.1	258.3	8.6	29.9
10-17 years	3	3	42	1,256	11,288,443	7,777,151,743	0.0	418.7	14.0	29.9
17-40 years	2	2	37	1,110	36,166,650	23,421,361,017	0.0	555.0	18.5	30.0
40-65 years	0	0	0	0	34,311,956	28,444,559,754	0.0	---	---	---
65+ years	0	0	0	0	12,474,746	10,843,812,617	0.0	---	---	---
<b><i>Zonisamide</i></b>										
0-2 years	108	109	612	19,681	3,812,846	1,275,911,969	2.8	182.2	5.7	32.2
2-5 years	164	167	1,138	37,900	5,830,329	2,894,602,738	2.8	231.1	6.9	33.3
5-10 years	377	394	2,968	95,586	8,447,162	5,141,935,333	4.5	253.5	7.9	32.2
10-17 years	1,395	1,471	9,245	301,544	11,288,443	7,777,151,743	12.4	216.2	6.6	32.6
17-40 years	8,661	9,211	40,031	1,289,789	36,166,650	23,421,361,017	23.9	148.9	4.6	32.2
40-65 years	10,545	11,365	52,688	1,815,281	34,311,956	28,444,559,754	30.7	172.1	5.0	34.5
65+ years	1,971	2,112	11,069	426,704	12,474,746	10,843,812,617	15.8	216.5	5.6	38.5

**Table 3a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Sex**

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Acetazolamide</b>									
Female	130,157	381,914	10,850,208	62,049,909	54,465,384,511	209.8	83.4	2.9	28.4
Male	98,654	224,819	5,689,079	59,118,797	50,463,171,904	166.9	57.7	2.3	25.3
Unknown	163	419	11,270	120,385	144,678,338	135.4	69.1	2.6	26.9
<b>Carbamazepine</b>									
Female	181,928	2,045,856	77,184,899	62,049,909	54,465,384,511	293.2	424.3	11.2	37.7
Male	131,652	1,675,412	62,660,979	59,118,797	50,463,171,904	222.7	476.0	12.7	37.4
Unknown	250	2,741	103,281	120,385	144,678,338	207.7	413.1	11.0	37.7
<b>Clobazam</b>									
Female	330	1,143	36,912	62,049,909	54,465,384,511	0.5	111.9	3.5	32.3
Male	361	1,264	41,434	59,118,797	50,463,171,904	0.6	114.8	3.5	32.8
Unknown	0	0	0	120,385	144,678,338	0.0	---	---	---
<b>Clonazepam</b>									
Female	1,271,059	9,996,389	316,867,025	62,049,909	54,465,384,511	2,048.4	249.3	7.9	31.7
Male	693,149	5,625,906	179,077,769	59,118,797	50,463,171,904	1,172.5	258.4	8.1	31.8
Unknown	1,601	10,279	304,890	120,385	144,678,338	1,329.9	190.4	6.4	29.7
<b>Diazepam</b>									
Female	1,842,969	6,100,748	130,885,760	62,049,909	54,465,384,511	2,970.1	71.0	3.3	21.5
Male	1,062,908	3,839,690	88,078,969	59,118,797	50,463,171,904	1,797.9	82.9	3.6	22.9
Unknown	2,365	6,509	127,532	120,385	144,678,338	1,964.5	53.9	2.8	19.6
<b>Ethosuxamide</b>									
Female	5,091	63,950	2,280,797	62,049,909	54,465,384,511	8.2	448.0	12.6	35.7
Male	3,364	40,582	1,433,008	59,118,797	50,463,171,904	5.7	426.0	12.1	35.3
Unknown	17	286	8,962	120,385	144,678,338	14.1	527.2	16.8	31.3
<b>Ezogabine</b>									
Female	32	94	2,761	62,049,909	54,465,384,511	0.1	86.3	2.9	29.4
Male	26	38	1,296	59,118,797	50,463,171,904	0.0	49.8	1.5	34.1
Unknown	0	0	0	120,385	144,678,338	0.0	---	---	---

**Table 3a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Sex**

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b><i>Felbamate</i></b>									
Female	1,621	28,925	1,026,638	62,049,909	54,465,384,511	2.6	633.3	17.8	35.5
Male	1,605	30,629	1,043,396	59,118,797	50,463,171,904	2.7	650.1	19.1	34.1
Unknown	7	78	2,267	120,385	144,678,338	5.8	323.9	11.1	29.1
<b><i>Gabapentin</i></b>									
Female	1,929,856	13,637,681	501,306,752	62,049,909	54,465,384,511	3,110.2	259.8	7.1	36.8
Male	1,158,776	7,591,837	279,194,694	59,118,797	50,463,171,904	1,960.1	240.9	6.6	36.8
Unknown	1,573	8,907	299,468	120,385	144,678,338	1,306.6	190.4	5.7	33.6
<b><i>Lacosamide</i></b>									
Female	8,378	59,874	1,961,597	62,049,909	54,465,384,511	13.5	234.1	7.1	32.8
Male	6,354	47,938	1,565,632	59,118,797	50,463,171,904	10.7	246.4	7.5	32.7
Unknown	15	79	2,619	120,385	144,678,338	12.5	174.6	5.3	33.2
<b><i>Lamotrigine</i></b>									
Female	478,885	5,197,994	184,984,274	62,049,909	54,465,384,511	771.8	386.3	10.9	35.6
Male	246,723	2,797,313	99,449,964	59,118,797	50,463,171,904	417.3	403.1	11.3	35.6
Unknown	822	7,829	265,705	120,385	144,678,338	682.8	323.2	9.5	33.9
<b><i>Levetiracetam</i></b>									
Female	188,960	1,871,843	65,895,041	62,049,909	54,465,384,511	304.5	348.7	9.9	35.2
Male	154,301	1,561,683	55,255,313	59,118,797	50,463,171,904	261.0	358.1	10.1	35.4
Unknown	268	2,597	92,612	120,385	144,678,338	222.6	345.6	9.7	35.7
<b><i>Lorazepam</i></b>									
Female	2,274,304	12,075,102	310,644,413	62,049,909	54,465,384,511	3,665.3	136.6	5.3	25.7
Male	1,109,700	5,450,861	139,525,053	59,118,797	50,463,171,904	1,877.1	125.7	4.9	25.6
Unknown	2,325	9,175	219,136	120,385	144,678,338	1,931.3	94.3	3.9	23.9
<b><i>Mephenytoin</i></b>									
Female	1	1	30	62,049,909	54,465,384,511	0.0	30.0	1.0	30.0
Male	0	0	0	59,118,797	50,463,171,904	0.0	---	---	---
Unknown	0	0	0	120,385	144,678,338	0.0	---	---	---



**Table 3a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Sex**

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b><i>Oxcarbazepine</i></b>									
Female	149,708	1,346,396	45,470,734	62,049,909	54,465,384,511	241.3	303.7	9.0	33.8
Male	112,166	1,153,823	38,654,522	59,118,797	50,463,171,904	189.7	344.6	10.3	33.5
Unknown	363	3,345	107,468	120,385	144,678,338	301.5	296.1	9.2	32.1
<b><i>Phenobarbital</i></b>									
Female	42,541	513,528	19,318,147	62,049,909	54,465,384,511	68.6	454.1	12.1	37.6
Male	35,639	422,207	15,590,133	59,118,797	50,463,171,904	60.3	437.4	11.8	36.9
Unknown	54	618	19,375	120,385	144,678,338	44.9	358.8	11.4	31.4
<b><i>Phenytoin, phenytoin sodium</i></b>									
Female	152,605	2,118,709	77,846,051	62,049,909	54,465,384,511	245.9	510.1	13.9	36.7
Male	171,364	2,459,176	92,609,296	59,118,797	50,463,171,904	289.9	540.4	14.4	37.7
Unknown	174	2,387	85,222	120,385	144,678,338	144.5	489.8	13.7	35.7
<b><i>Pregabalin</i></b>									
Female	528,696	3,290,038	109,620,439	62,049,909	54,465,384,511	852.0	207.3	6.2	33.3
Male	270,191	1,596,269	53,736,314	59,118,797	50,463,171,904	457.0	198.9	5.9	33.7
Unknown	336	1,942	67,071	120,385	144,678,338	279.1	199.6	5.8	34.5
<b><i>Primidone</i></b>									
Female	59,696	649,076	25,702,712	62,049,909	54,465,384,511	96.2	430.6	10.9	39.6
Male	48,565	521,701	21,449,117	59,118,797	50,463,171,904	82.1	441.7	10.7	41.1
Unknown	43	326	11,346	120,385	144,678,338	35.7	263.9	7.6	34.8
<b><i>Rufinamide</i></b>									
Female	976	9,018	287,197	62,049,909	54,465,384,511	1.6	294.3	9.2	31.8
Male	1,077	10,075	327,435	59,118,797	50,463,171,904	1.8	304.0	9.4	32.5
Unknown	2	30	898	120,385	144,678,338	1.7	449.0	15.0	29.9
<b><i>Tiagabine</i></b>									
Female	23,877	149,059	4,799,915	62,049,909	54,465,384,511	38.5	201.0	6.2	32.2
Male	14,157	92,298	2,936,662	59,118,797	50,463,171,904	23.9	207.4	6.5	31.8
Unknown	42	224	7,113	120,385	144,678,338	34.9	169.4	5.3	31.8

**Table 3a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Sex**

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b><i>Topiramate</i></b>									
Female	751,283	5,947,845	210,520,738	62,049,909	54,465,384,511	1,210.8	280.2	7.9	35.4
Male	179,054	1,258,442	43,940,163	59,118,797	50,463,171,904	302.9	245.4	7.0	34.9
Unknown	1,140	8,617	286,782	120,385	144,678,338	947.0	251.6	7.6	33.3
<b><i>Valproic acid</i></b>									
Female	26,392	167,247	6,917,498	62,049,909	54,465,384,511	42.5	262.1	6.3	41.4
Male	23,953	172,366	6,874,008	59,118,797	50,463,171,904	40.5	287.0	7.2	39.9
Unknown	18	110	4,290	120,385	144,678,338	15.0	238.3	6.1	39.0
<b><i>Vigabatrin</i></b>									
Female	220	2,155	65,946	62,049,909	54,465,384,511	0.4	299.8	9.8	30.6
Male	215	1,881	56,983	59,118,797	50,463,171,904	0.4	265.0	8.7	30.3
Unknown	2	10	290	120,385	144,678,338	1.7	145.0	5.0	29.0
<b><i>Zonisamide</i></b>									
Female	66,079	525,403	17,950,082	62,049,909	54,465,384,511	106.5	271.6	8.0	34.2
Male	27,109	263,028	9,053,134	59,118,797	50,463,171,904	45.9	334.0	9.7	34.4
Unknown	97	736	22,854	120,385	144,678,338	80.6	235.6	7.6	31.1

**Table 3b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Sex**

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Acetazolamide</b>										
Female	86,651	95,164	170,823	4,038,759	49,791,335	40,952,408,517	174.0	46.6	2.0	23.6
Male	73,068	80,339	124,385	2,557,544	47,334,236	38,810,005,275	154.4	35.0	1.7	20.6
Unknown	114	124	205	4,913	109,134	110,802,126	104.5	43.1	1.8	24.0
<b>Carbamazepine</b>										
Female	50,870	59,656	290,195	11,857,875	49,791,335	40,952,408,517	102.2	233.1	5.7	40.9
Male	36,119	42,381	235,494	9,502,250	47,334,236	38,810,005,275	76.3	263.1	6.5	40.4
Unknown	73	80	623	30,587	109,134	110,802,126	66.9	419.0	8.5	49.1
<b>Clobazam</b>										
Female	15	15	52	1,654	49,791,335	40,952,408,517	0.0	110.3	3.5	31.8
Male	25	25	69	2,239	47,334,236	38,810,005,275	0.1	89.6	2.8	32.4
Unknown	0	0	0	0	109,134	110,802,126	0.0	---	---	---
<b>Clonazepam</b>										
Female	584,110	707,299	2,989,934	92,663,680	49,791,335	40,952,408,517	1,173.1	158.6	5.1	31.0
Male	329,356	390,207	1,813,398	56,558,829	47,334,236	38,810,005,275	695.8	171.7	5.5	31.2
Unknown	836	950	4,126	119,714	109,134	110,802,126	766.0	143.2	4.9	29.0
<b>Diazepam</b>										
Female	1,205,279	1,442,412	2,762,758	47,873,639	49,791,335	40,952,408,517	2,420.7	39.7	2.3	17.3
Male	711,093	824,988	1,709,115	31,912,299	47,334,236	38,810,005,275	1,502.3	44.9	2.4	18.7
Unknown	1,616	1,788	3,235	51,825	109,134	110,802,126	1,480.7	32.1	2.0	16.0
<b>Ethosuxamide</b>										
Female	1,664	1,872	17,170	602,232	49,791,335	40,952,408,517	3.3	361.9	10.3	35.1
Male	1,183	1,307	11,825	413,571	47,334,236	38,810,005,275	2.5	349.6	10.0	35.0
Unknown	10	12	154	5,004	109,134	110,802,126	9.2	500.4	15.4	32.5
<b>Ezogabine</b>										
Female	1	1	1	30	49,791,335	40,952,408,517	0.0	30.0	1.0	30.0
Male	0	0	0	0	47,334,236	38,810,005,275	0.0	---	---	---
Unknown	0	0	0	0	109,134	110,802,126	0.0	---	---	---

**Table 3b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Sex**

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b><i>Felbamate</i></b>										
Female	87	118	1,097	43,625	49,791,335	40,952,408,517	0.2	501.4	12.6	39.8
Male	86	95	1,226	49,019	47,334,236	38,810,005,275	0.2	570.0	14.3	40.0
Unknown	1	1	1	30	109,134	110,802,126	0.9	30.0	1.0	30.0
<b><i>Gabapentin</i></b>										
Female	989,631	1,142,164	4,990,519	187,642,217	49,791,335	40,952,408,517	1,987.6	189.6	5.0	37.6
Male	634,514	721,424	3,040,653	114,080,536	47,334,236	38,810,005,275	1,340.5	179.8	4.8	37.5
Unknown	864	935	3,549	116,070	109,134	110,802,126	791.7	134.3	4.1	32.7
<b><i>Lacosamide</i></b>										
Female	771	784	3,965	122,344	49,791,335	40,952,408,517	1.5	158.7	5.1	30.9
Male	539	554	2,883	90,663	47,334,236	38,810,005,275	1.1	168.2	5.3	31.4
Unknown	2	2	11	281	109,134	110,802,126	1.8	140.5	5.5	25.5
<b><i>Lamotrigine</i></b>										
Female	147,419	161,571	1,230,550	44,177,275	49,791,335	40,952,408,517	296.1	299.7	8.3	35.9
Male	80,556	87,446	703,447	25,126,610	47,334,236	38,810,005,275	170.2	311.9	8.7	35.7
Unknown	355	380	3,051	99,291	109,134	110,802,126	325.3	279.7	8.6	32.5
<b><i>Levetiracetam</i></b>										
Female	60,320	64,288	443,765	15,699,013	49,791,335	40,952,408,517	121.1	260.3	7.4	35.4
Male	53,674	57,084	389,834	13,865,386	47,334,236	38,810,005,275	113.4	258.3	7.3	35.6
Unknown	94	100	771	29,006	109,134	110,802,126	86.1	308.6	8.2	37.6
<b><i>Lorazepam</i></b>										
Female	1,423,065	1,809,936	5,246,688	120,555,500	49,791,335	40,952,408,517	2,858.1	84.7	3.7	23.0
Male	713,695	860,803	2,511,277	57,549,812	47,334,236	38,810,005,275	1,507.8	80.6	3.5	22.9
Unknown	1,471	1,686	4,596	103,734	109,134	110,802,126	1,347.9	70.5	3.1	22.6
<b><i>Mephenytoin</i></b>										
Female	1	1	1	30	49,791,335	40,952,408,517	0.0	30.0	1.0	30.0
Male	0	0	0	0	47,334,236	38,810,005,275	0.0	---	---	---
Unknown	0	0	0	0	109,134	110,802,126	0.0	---	---	---

**Table 3b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Sex**

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b><i>Oxcarbazepine</i></b>										
Female	43,766	47,970	289,791	9,692,583	49,791,335	40,952,408,517	87.9	221.5	6.6	33.4
Male	37,748	41,323	296,870	9,775,959	47,334,236	38,810,005,275	79.7	259.0	7.9	32.9
Unknown	121	128	844	26,108	109,134	110,802,126	110.9	215.8	7.0	30.9
<b><i>Phenobarbital</i></b>										
Female	11,548	13,033	56,694	2,147,540	49,791,335	40,952,408,517	23.2	186.0	4.9	37.9
Male	9,735	10,618	44,041	1,549,954	47,334,236	38,810,005,275	20.6	159.2	4.5	35.2
Unknown	19	19	183	5,026	109,134	110,802,126	17.4	264.5	9.6	27.5
<b><i>Phenytoin, phenytoin</i></b>										
Female	40,130	44,706	288,159	11,067,444	49,791,335	40,952,408,517	80.6	275.8	7.2	38.4
Male	47,361	53,199	348,209	13,856,134	47,334,236	38,810,005,275	100.1	292.6	7.4	39.8
Unknown	70	73	637	21,450	109,134	110,802,126	64.1	306.4	9.1	33.7
<b><i>Pregabalin</i></b>										
Female	181,251	195,146	844,348	28,252,563	49,791,335	40,952,408,517	364.0	155.9	4.7	33.5
Male	98,886	105,598	416,675	14,003,995	47,334,236	38,810,005,275	208.9	141.6	4.2	33.6
Unknown	142	153	751	26,435	109,134	110,802,126	130.1	186.2	5.3	35.2
<b><i>Primidone</i></b>										
Female	20,588	23,290	142,689	5,994,861	49,791,335	40,952,408,517	41.3	291.2	6.9	42.0
Male	19,550	22,411	138,122	6,071,186	47,334,236	38,810,005,275	41.3	310.5	7.1	44.0
Unknown	18	19	92	3,301	109,134	110,802,126	16.5	183.4	5.1	35.9
<b><i>Rufinamide</i></b>										
Female	48	49	474	15,183	49,791,335	40,952,408,517	0.1	316.3	9.9	32.0
Male	49	50	392	12,632	47,334,236	38,810,005,275	0.1	257.8	8.0	32.2
Unknown	0	0	0	0	109,134	110,802,126	0.0	---	---	---
<b><i>Tiagabine</i></b>										
Female	5,557	5,886	22,758	722,542	49,791,335	40,952,408,517	11.2	130.0	4.1	31.7
Male	3,667	3,831	15,498	479,308	47,334,236	38,810,005,275	7.7	130.7	4.2	30.9
Unknown	12	12	45	1,319	109,134	110,802,126	11.0	109.9	3.8	29.3

**Table 3b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Sex**

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b><i>Topiramate</i></b>										
Female	318,036	355,850	1,860,672	66,189,034	49,791,335	40,952,408,517	638.7	208.1	5.9	35.6
Male	75,571	81,973	361,788	12,712,528	47,334,236	38,810,005,275	159.7	168.2	4.8	35.1
Unknown	573	631	3,577	119,799	109,134	110,802,126	525.0	209.1	6.2	33.5
<b><i>Valproic acid</i></b>										
Female	10,739	12,848	57,733	2,758,691	49,791,335	40,952,408,517	21.6	256.9	5.4	47.8
Male	10,595	12,742	62,000	2,829,264	47,334,236	38,810,005,275	22.4	267.0	5.9	45.6
Unknown	6	6	47	1,920	109,134	110,802,126	5.5	320.0	7.8	40.9
<b><i>Vigabatrin</i></b>										
Female	28	29	251	7,733	49,791,335	40,952,408,517	0.1	276.2	9.0	30.8
Male	22	22	182	5,466	47,334,236	38,810,005,275	0.0	248.5	8.3	30.0
Unknown	0	0	0	0	109,134	110,802,126	0.0	---	---	---
<b><i>Zonisamide</i></b>										
Female	16,749	18,053	86,194	2,923,209	49,791,335	40,952,408,517	33.6	174.5	5.1	33.9
Male	6,319	6,749	38,030	1,285,184	47,334,236	38,810,005,275	13.3	203.4	6.0	33.8
Unknown	26	27	161	5,017	109,134	110,802,126	23.8	193.0	6.2	31.2

Table 4a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Year

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Acetazolamide</b>									
2004	15,890	35,585	965,186	23,852,540	7,080,534,600	66.6	60.7	2.2	27.1
2005	16,962	35,776	952,941	24,633,820	7,256,197,886	68.9	56.2	2.1	26.6
2006	19,888	39,076	1,049,334	26,418,643	7,874,284,484	75.3	52.8	2.0	26.9
2007	29,707	62,497	1,681,206	33,458,945	9,332,406,812	88.8	56.6	2.1	26.9
2008	47,591	105,324	2,811,911	60,531,945	17,574,413,035	78.6	59.1	2.2	26.7
2009	44,759	96,000	2,601,820	56,699,065	16,989,471,078	78.9	58.1	2.1	27.1
2010	45,000	95,291	2,605,750	55,259,872	16,430,588,163	81.4	57.9	2.1	27.3
2011	43,207	90,380	2,532,205	54,197,789	16,009,092,991	79.7	58.6	2.1	28.0
2012	25,199	47,223	1,350,204	34,157,358	6,526,245,704	73.8	53.6	1.9	28.6
<b>Carbamazepine</b>									
2004	52,883	324,857	11,904,528	23,852,540	7,080,534,600	221.7	225.1	6.1	36.6
2005	51,677	302,870	11,257,288	24,633,820	7,256,197,886	209.8	217.8	5.9	37.2
2006	50,242	280,687	10,967,863	26,418,643	7,874,284,484	190.2	218.3	5.6	39.1
2007	81,031	440,026	15,999,114	33,458,945	9,332,406,812	242.2	197.4	5.4	36.4
2008	108,194	672,778	24,073,319	60,531,945	17,574,413,035	178.7	222.5	6.2	35.8
2009	92,954	529,850	19,895,000	56,699,065	16,989,471,078	163.9	214.0	5.7	37.5
2010	89,818	491,758	18,866,518	55,259,872	16,430,588,163	162.5	210.1	5.5	38.4
2011	86,553	456,222	17,925,419	54,197,789	16,009,092,991	159.7	207.1	5.3	39.3
2012	58,693	224,961	9,060,110	34,157,358	6,526,245,704	171.8	154.4	3.8	40.3
<b>Clobazam</b>									
2004	0	0	0	23,852,540	7,080,534,600	0.0	---	---	---
2005	0	0	0	24,633,820	7,256,197,886	0.0	---	---	---
2006	0	0	0	26,418,643	7,874,284,484	0.0	---	---	---
2007	0	0	0	33,458,945	9,332,406,812	0.0	---	---	---
2008	0	0	0	60,531,945	17,574,413,035	0.0	---	---	---
2009	0	0	0	56,699,065	16,989,471,078	0.0	---	---	---
2010	0	0	0	55,259,872	16,430,588,163	0.0	---	---	---
2011	8	8	240	54,197,789	16,009,092,991	0.0	30.0	1.0	30.0
2012	688	2,399	78,106	34,157,358	6,526,245,704	2.0	113.5	3.5	32.6

Table 4a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Year

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Clonazepam</b>									
2004	216,286	1,064,047	32,486,032	23,852,540	7,080,534,600	906.8	150.2	4.9	30.5
2005	230,700	1,090,740	33,626,375	24,633,820	7,256,197,886	936.5	145.8	4.7	30.8
2006	225,054	942,697	30,197,823	26,418,643	7,874,284,484	851.9	134.2	4.2	32.0
2007	323,654	1,323,745	42,076,792	33,458,945	9,332,406,812	967.3	130.0	4.1	31.8
2008	585,827	2,583,865	80,954,756	60,531,945	17,574,413,035	967.8	138.2	4.4	31.3
2009	601,408	2,638,788	83,298,124	56,699,065	16,989,471,078	1,060.7	138.5	4.4	31.6
2010	588,800	2,599,630	82,996,555	55,259,872	16,430,588,163	1,065.5	141.0	4.4	31.9
2011	557,944	2,306,724	74,831,228	54,197,789	16,009,092,991	1,029.5	134.1	4.1	32.4
2012	337,924	1,082,338	35,781,999	34,157,358	6,526,245,704	989.3	105.9	3.2	33.1
<b>Diazepam</b>									
2004	299,192	905,119	20,921,142	23,852,540	7,080,534,600	1,254.3	69.9	3.0	23.1
2005	310,102	874,571	19,901,192	24,633,820	7,256,197,886	1,258.8	64.2	2.8	22.8
2006	302,394	697,265	14,995,757	26,418,643	7,874,284,484	1,144.6	49.6	2.3	21.5
2007	400,330	942,875	21,049,598	33,458,945	9,332,406,812	1,196.5	52.6	2.4	22.3
2008	682,968	1,636,853	35,445,064	60,531,945	17,574,413,035	1,128.3	51.9	2.4	21.7
2009	663,598	1,577,398	34,180,213	56,699,065	16,989,471,078	1,170.4	51.5	2.4	21.7
2010	628,700	1,486,734	32,307,037	55,259,872	16,430,588,163	1,137.7	51.4	2.4	21.7
2011	558,171	1,255,541	27,628,428	54,197,789	16,009,092,991	1,029.9	49.5	2.2	22.0
2012	290,035	570,591	12,663,830	34,157,358	6,526,245,704	849.1	43.7	2.0	22.2
<b>Ethosuxamide</b>									
2004	1,192	6,991	252,959	23,852,540	7,080,534,600	5.0	212.2	5.9	36.2
2005	1,208	6,960	251,981	24,633,820	7,256,197,886	4.9	208.6	5.8	36.2
2006	1,211	6,759	250,304	26,418,643	7,874,284,484	4.6	206.7	5.6	37.0
2007	1,517	8,419	301,885	33,458,945	9,332,406,812	4.5	199.0	5.5	35.9
2008	2,695	16,409	567,876	60,531,945	17,574,413,035	4.5	210.7	6.1	34.6
2009	2,859	17,190	599,955	56,699,065	16,989,471,078	5.0	209.8	6.0	34.9
2010	2,992	17,943	634,540	55,259,872	16,430,588,163	5.4	212.1	6.0	35.4
2011	2,962	16,772	595,215	54,197,789	16,009,092,991	5.5	201.0	5.7	35.5
2012	1,814	7,375	268,052	34,157,358	6,526,245,704	5.3	147.8	4.1	36.3



Table 4a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Year

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Ezogabine</b>									
2004	0	0	0	23,852,540	7,080,534,600	0.0	---	---	---
2005	0	0	0	24,633,820	7,256,197,886	0.0	---	---	---
2006	0	0	0	26,418,643	7,874,284,484	0.0	---	---	---
2007	0	0	0	33,458,945	9,332,406,812	0.0	---	---	---
2008	0	0	0	60,531,945	17,574,413,035	0.0	---	---	---
2009	0	0	0	56,699,065	16,989,471,078	0.0	---	---	---
2010	0	0	0	55,259,872	16,430,588,163	0.0	---	---	---
2011	0	0	0	54,197,789	16,009,092,991	0.0	---	---	---
2012	58	132	4,057	34,157,358	6,526,245,704	0.2	69.9	2.3	30.7
<b>Felbamate</b>									
2004	509	4,135	141,606	23,852,540	7,080,534,600	2.1	278.2	8.1	34.2
2005	540	4,161	142,998	24,633,820	7,256,197,886	2.2	264.8	7.7	34.4
2006	552	4,175	147,768	26,418,643	7,874,284,484	2.1	267.7	7.6	35.4
2007	871	6,194	210,704	33,458,945	9,332,406,812	2.6	241.9	7.1	34.0
2008	1,354	10,831	366,540	60,531,945	17,574,413,035	2.2	270.7	8.0	33.8
2009	1,217	9,135	320,384	56,699,065	16,989,471,078	2.1	263.3	7.5	35.1
2010	1,211	8,752	310,717	55,259,872	16,430,588,163	2.2	256.6	7.2	35.5
2011	1,199	8,355	294,713	54,197,789	16,009,092,991	2.2	245.8	7.0	35.3
2012	815	3,894	136,871	34,157,358	6,526,245,704	2.4	167.9	4.8	35.1
<b>Gabapentin</b>									
2004	241,691	1,119,364	37,600,410	23,852,540	7,080,534,600	1,013.3	155.6	4.6	33.6
2005	244,263	1,064,868	36,707,337	24,633,820	7,256,197,886	991.6	150.3	4.4	34.5
2006	251,538	985,931	36,991,424	26,418,643	7,874,284,484	952.1	147.1	3.9	37.5
2007	501,829	1,937,383	68,251,721	33,458,945	9,332,406,812	1,499.8	136.0	3.9	35.2
2008	783,439	3,386,411	118,459,752	60,531,945	17,574,413,035	1,294.3	151.2	4.3	35.0
2009	810,267	3,311,617	119,906,340	56,699,065	16,989,471,078	1,429.1	148.0	4.1	36.2
2010	883,430	3,582,141	133,186,666	55,259,872	16,430,588,163	1,598.7	150.8	4.1	37.2
2011	951,689	3,761,325	145,658,745	54,197,789	16,009,092,991	1,756.0	153.1	4.0	38.7
2012	682,735	2,089,385	84,038,519	34,157,358	6,526,245,704	1,998.8	123.1	3.1	40.2

Table 4a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Year

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Lacosamide</b>									
2004	0	0	0	23,852,540	7,080,534,600	0.0	---	---	---
2005	0	0	0	24,633,820	7,256,197,886	0.0	---	---	---
2006	0	0	0	26,418,643	7,874,284,484	0.0	---	---	---
2007	0	0	0	33,458,945	9,332,406,812	0.0	---	---	---
2008	0	0	0	60,531,945	17,574,413,035	0.0	---	---	---
2009	2,373	7,324	226,679	56,699,065	16,989,471,078	4.2	95.5	3.1	31.0
2010	6,028	29,407	961,523	55,259,872	16,430,588,163	10.9	159.5	4.9	32.7
2011	8,165	44,640	1,457,664	54,197,789	16,009,092,991	15.1	178.5	5.5	32.7
2012	5,912	26,520	883,982	34,157,358	6,526,245,704	17.3	149.5	4.5	33.3
<b>Lamotrigine</b>									
2004	47,140	261,311	8,909,176	23,852,540	7,080,534,600	197.6	189.0	5.5	34.1
2005	62,565	341,976	11,790,865	24,633,820	7,256,197,886	254.0	188.5	5.5	34.5
2006	79,032	424,725	15,313,238	26,418,643	7,874,284,484	299.2	193.8	5.4	36.1
2007	130,388	697,069	24,275,591	33,458,945	9,332,406,812	389.7	186.2	5.3	34.8
2008	243,832	1,447,753	49,772,900	60,531,945	17,574,413,035	402.8	204.1	5.9	34.4
2009	243,150	1,428,806	50,327,841	56,699,065	16,989,471,078	428.8	207.0	5.9	35.2
2010	246,051	1,428,747	51,270,031	55,259,872	16,430,588,163	445.3	208.4	5.8	35.9
2011	243,747	1,334,273	48,873,316	54,197,789	16,009,092,991	449.7	200.5	5.5	36.6
2012	155,576	638,476	24,166,985	34,157,358	6,526,245,704	455.5	155.3	4.1	37.9
<b>Levetiracetam</b>									
2004	19,423	105,922	3,509,497	23,852,540	7,080,534,600	81.4	180.7	5.5	33.1
2005	22,529	123,649	4,183,023	24,633,820	7,256,197,886	91.5	185.7	5.5	33.8
2006	26,673	143,274	5,075,464	26,418,643	7,874,284,484	101.0	190.3	5.4	35.4
2007	54,962	286,683	9,677,187	33,458,945	9,332,406,812	164.3	176.1	5.2	33.8
2008	94,391	556,577	18,771,712	60,531,945	17,574,413,035	155.9	198.9	5.9	33.7
2009	100,736	574,549	20,031,100	56,699,065	16,989,471,078	177.7	198.8	5.7	34.9
2010	113,542	629,192	22,452,095	55,259,872	16,430,588,163	205.5	197.7	5.5	35.7
2011	124,593	664,570	24,339,150	54,197,789	16,009,092,991	229.9	195.3	5.3	36.6
2012	88,640	351,707	13,203,738	34,157,358	6,526,245,704	259.5	149.0	4.0	37.5

**Table 4a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Year**

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Lorazepam</b>									
2004	367,185	1,320,905	32,758,944	23,852,540	7,080,534,600	1,539.4	89.2	3.6	24.8
2005	387,785	1,334,765	32,802,871	24,633,820	7,256,197,886	1,574.2	84.6	3.4	24.6
2006	374,367	1,105,952	27,374,212	26,418,643	7,874,284,484	1,417.1	73.1	3.0	24.8
2007	537,204	1,631,239	41,421,342	33,458,945	9,332,406,812	1,605.6	77.1	3.0	25.4
2008	882,782	2,865,765	72,959,942	60,531,945	17,574,413,035	1,458.4	82.6	3.2	25.5
2009	889,842	2,870,587	73,574,738	56,699,065	16,989,471,078	1,569.4	82.7	3.2	25.6
2010	873,499	2,812,530	73,086,075	55,259,872	16,430,588,163	1,580.7	83.7	3.2	26.0
2011	804,732	2,448,929	65,402,503	54,197,789	16,009,092,991	1,484.8	81.3	3.0	26.7
2012	457,895	1,144,466	31,007,975	34,157,358	6,526,245,704	1,340.5	67.7	2.5	27.1
<b>Mephenytoin</b>									
2004	0	0	0	23,852,540	7,080,534,600	0.0	---	---	---
2005	1	1	30	24,633,820	7,256,197,886	0.0	30.0	1.0	30.0
2006	0	0	0	26,418,643	7,874,284,484	0.0	---	---	---
2007	0	0	0	33,458,945	9,332,406,812	0.0	---	---	---
2008	0	0	0	60,531,945	17,574,413,035	0.0	---	---	---
2009	0	0	0	56,699,065	16,989,471,078	0.0	---	---	---
2010	0	0	0	55,259,872	16,430,588,163	0.0	---	---	---
2011	0	0	0	54,197,789	16,009,092,991	0.0	---	---	---
2012	0	0	0	34,157,358	6,526,245,704	0.0	---	---	---
<b>Oxcarbazepine</b>									
2004	40,221	208,429	6,374,474	23,852,540	7,080,534,600	168.6	158.5	5.2	30.6
2005	39,513	202,926	6,435,211	24,633,820	7,256,197,886	160.4	162.9	5.1	31.7
2006	34,352	175,680	5,912,946	26,418,643	7,874,284,484	130.0	172.1	5.1	33.7
2007	47,807	249,889	8,228,701	33,458,945	9,332,406,812	142.9	172.1	5.2	32.9
2008	75,828	440,494	14,593,534	60,531,945	17,574,413,035	125.3	192.5	5.8	33.1
2009	69,225	380,254	12,955,996	56,699,065	16,989,471,078	122.1	187.2	5.5	34.1
2010	68,127	362,127	12,553,688	55,259,872	16,430,588,163	123.3	184.3	5.3	34.7
2011	65,496	333,696	11,720,225	54,197,789	16,009,092,991	120.8	178.9	5.1	35.1
2012	38,658	150,069	5,457,949	34,157,358	6,526,245,704	113.2	141.2	3.9	36.4

Table 4a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Year

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b><i>Phenobarbital</i></b>									
2004	17,733	120,965	4,119,786	23,852,540	7,080,534,600	74.3	232.3	6.8	34.1
2005	16,981	110,716	3,797,727	24,633,820	7,256,197,886	68.9	223.6	6.5	34.3
2006	14,354	76,058	2,942,990	26,418,643	7,874,284,484	54.3	205.0	5.3	38.7
2007	19,155	97,343	3,683,608	33,458,945	9,332,406,812	57.2	192.3	5.1	37.8
2008	25,469	149,650	5,483,373	60,531,945	17,574,413,035	42.1	215.3	5.9	36.6
2009	23,575	132,712	5,009,684	56,699,065	16,989,471,078	41.6	212.5	5.6	37.7
2010	20,618	114,997	4,433,529	55,259,872	16,430,588,163	37.3	215.0	5.6	38.6
2011	18,572	93,190	3,729,153	54,197,789	16,009,092,991	34.3	200.8	5.0	40.0
2012	11,507	40,722	1,727,805	34,157,358	6,526,245,704	33.7	150.2	3.5	42.4
<b><i>Phenytoin, phenytoin sodium</i></b>									
2004	62,506	429,127	15,374,921	23,852,540	7,080,534,600	262.1	246.0	6.9	35.8
2005	59,707	390,738	14,182,747	24,633,820	7,256,197,886	242.4	237.5	6.5	36.3
2006	55,256	333,403	13,077,429	26,418,643	7,874,284,484	209.2	236.7	6.0	39.2
2007	102,176	597,313	21,295,612	33,458,945	9,332,406,812	305.4	208.4	5.8	35.7
2008	123,161	872,372	30,810,398	60,531,945	17,574,413,035	203.5	250.2	7.1	35.3
2009	96,775	632,714	23,774,197	56,699,065	16,989,471,078	170.7	245.7	6.5	37.6
2010	90,195	562,531	21,685,780	55,259,872	16,430,588,163	163.2	240.4	6.2	38.6
2011	85,350	512,435	20,240,454	54,197,789	16,009,092,991	157.5	237.1	6.0	39.5
2012	58,917	249,639	10,099,031	34,157,358	6,526,245,704	172.5	171.4	4.2	40.5
<b><i>Pregabalin</i></b>									
2004	0	0	0	23,852,540	7,080,534,600	0.0	---	---	---
2005	9,644	15,513	440,057	24,633,820	7,256,197,886	39.1	45.6	1.6	28.4
2006	53,521	165,546	5,166,714	26,418,643	7,874,284,484	202.6	96.5	3.1	31.2
2007	170,580	563,800	17,515,621	33,458,945	9,332,406,812	509.8	102.7	3.3	31.1
2008	321,350	1,282,617	41,221,799	60,531,945	17,574,413,035	530.9	128.3	4.0	32.1
2009	218,268	946,718	31,761,864	56,699,065	16,989,471,078	385.0	145.5	4.3	33.5
2010	190,921	818,614	28,271,083	55,259,872	16,430,588,163	345.5	148.1	4.3	34.5
2011	174,347	721,647	25,716,351	54,197,789	16,009,092,991	321.7	147.5	4.1	35.6
2012	112,691	373,794	13,330,335	34,157,358	6,526,245,704	329.9	118.3	3.3	35.7

Table 4a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Year

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Primidone</b>									
2004	11,351	65,559	2,485,824	23,852,540	7,080,534,600	47.6	219.0	5.8	37.9
2005	11,475	63,714	2,455,453	24,633,820	7,256,197,886	46.6	214.0	5.6	38.5
2006	11,843	59,465	2,505,527	26,418,643	7,874,284,484	44.8	211.6	5.0	42.1
2007	27,128	129,091	4,869,279	33,458,945	9,332,406,812	81.1	179.5	4.8	37.7
2008	37,348	214,524	8,034,584	60,531,945	17,574,413,035	61.7	215.1	5.7	37.5
2009	33,722	182,609	7,247,209	56,699,065	16,989,471,078	59.5	214.9	5.4	39.7
2010	34,419	180,578	7,423,946	55,259,872	16,430,588,163	62.3	215.7	5.2	41.1
2011	36,318	178,528	7,779,826	54,197,789	16,009,092,991	67.0	214.2	4.9	43.6
2012	27,848	97,035	4,361,527	34,157,358	6,526,245,704	81.5	156.6	3.5	44.9
<b>Rufinamide</b>									
2004	0	0	0	23,852,540	7,080,534,600	0.0	---	---	---
2005	0	0	0	24,633,820	7,256,197,886	0.0	---	---	---
2006	0	0	0	26,418,643	7,874,284,484	0.0	---	---	---
2007	0	0	0	33,458,945	9,332,406,812	0.0	---	---	---
2008	0	0	0	60,531,945	17,574,413,035	0.0	---	---	---
2009	840	3,735	116,870	56,699,065	16,989,471,078	1.5	139.1	4.4	31.3
2010	991	6,283	200,367	55,259,872	16,430,588,163	1.8	202.2	6.3	31.9
2011	1,024	6,492	209,609	54,197,789	16,009,092,991	1.9	204.7	6.3	32.3
2012	553	2,613	88,684	34,157,358	6,526,245,704	1.6	160.4	4.7	33.9
<b>Tiagabine</b>									
2004	19,591	71,888	2,140,004	23,852,540	7,080,534,600	82.1	109.2	3.7	29.8
2005	12,157	49,626	1,525,552	24,633,820	7,256,197,886	49.4	125.5	4.1	30.7
2006	4,492	19,329	648,582	26,418,643	7,874,284,484	17.0	144.4	4.3	33.6
2007	4,933	23,115	752,661	33,458,945	9,332,406,812	14.7	152.6	4.7	32.6
2008	5,779	30,346	1,006,963	60,531,945	17,574,413,035	9.5	174.2	5.3	33.2
2009	3,688	18,673	651,806	56,699,065	16,989,471,078	6.5	176.7	5.1	34.9
2010	2,763	14,000	494,548	55,259,872	16,430,588,163	5.0	179.0	5.1	35.3
2011	2,006	10,414	373,736	54,197,789	16,009,092,991	3.7	186.3	5.2	35.9
2012	1,075	4,190	149,838	34,157,358	6,526,245,704	3.1	139.4	3.9	35.8

Table 4a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Year

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Topiramate</b>									
2004	86,581	403,068	13,227,940	23,852,540	7,080,534,600	363.0	152.8	4.7	32.8
2005	96,000	429,640	14,255,819	24,633,820	7,256,197,886	389.7	148.5	4.5	33.2
2006	100,698	445,291	15,798,389	26,418,643	7,874,284,484	381.2	156.9	4.4	35.5
2007	146,461	652,047	22,627,927	33,458,945	9,332,406,812	437.7	154.5	4.5	34.7
2008	264,379	1,243,406	42,951,885	60,531,945	17,574,413,035	436.8	162.5	4.7	34.5
2009	261,939	1,202,301	42,365,970	56,699,065	16,989,471,078	462.0	161.7	4.6	35.2
2010	267,171	1,221,055	43,734,282	55,259,872	16,430,588,163	483.5	163.7	4.6	35.8
2011	256,062	1,100,880	40,266,231	54,197,789	16,009,092,991	472.5	157.3	4.3	36.6
2012	155,807	517,216	19,519,240	34,157,358	6,526,245,704	456.1	125.3	3.3	37.7
<b>Valproic acid</b>									
2004	3,610	13,706	562,553	23,852,540	7,080,534,600	15.1	155.8	3.8	41.0
2005	8,984	23,236	1,035,745	24,633,820	7,256,197,886	36.5	115.3	2.6	44.6
2006	7,674	25,570	983,491	26,418,643	7,874,284,484	29.0	128.2	3.3	38.5
2007	11,856	43,098	1,573,022	33,458,945	9,332,406,812	35.4	132.7	3.6	36.5
2008	15,526	66,325	2,558,310	60,531,945	17,574,413,035	25.6	164.8	4.3	38.6
2009	13,285	55,306	2,253,912	56,699,065	16,989,471,078	23.4	169.7	4.2	40.8
2010	11,634	49,542	2,082,574	55,259,872	16,430,588,163	21.1	179.0	4.3	42.0
2011	10,191	42,785	1,846,944	54,197,789	16,009,092,991	18.8	181.2	4.2	43.2
2012	6,370	20,155	899,245	34,157,358	6,526,245,704	18.6	141.2	3.2	44.6
<b>Vigabatrin</b>									
2004	0	0	0	23,852,540	7,080,534,600	0.0	---	---	---
2005	0	0	0	24,633,820	7,256,197,886	0.0	---	---	---
2006	0	0	0	26,418,643	7,874,284,484	0.0	---	---	---
2007	0	0	0	33,458,945	9,332,406,812	0.0	---	---	---
2008	0	0	0	60,531,945	17,574,413,035	0.0	---	---	---
2009	65	119	3,590	56,699,065	16,989,471,078	0.1	55.2	1.8	30.2
2010	235	1,384	43,206	55,259,872	16,430,588,163	0.4	183.9	5.9	31.2
2011	274	1,792	53,905	54,197,789	16,009,092,991	0.5	196.7	6.5	30.1
2012	146	751	22,518	34,157,358	6,526,245,704	0.4	154.2	5.1	30.0

Table 4a. Summary of Prevalent AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Year

	Users	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Zonisamide</b>									
2004	12,819	56,696	1,783,243	23,852,540	7,080,534,600	53.7	139.1	4.4	31.5
2005	12,255	58,004	1,857,028	24,633,820	7,256,197,886	49.7	151.5	4.7	32.0
2006	9,996	50,123	1,681,899	26,418,643	7,874,284,484	37.8	168.3	5.0	33.6
2007	15,104	74,863	2,499,625	33,458,945	9,332,406,812	45.1	165.5	5.0	33.4
2008	25,987	138,582	4,672,498	60,531,945	17,574,413,035	42.9	179.8	5.3	33.7
2009	24,530	125,886	4,334,792	56,699,065	16,989,471,078	43.3	176.7	5.1	34.4
2010	23,558	120,459	4,224,889	55,259,872	16,430,588,163	42.6	179.3	5.1	35.1
2011	22,712	112,717	4,040,191	54,197,789	16,009,092,991	41.9	177.9	5.0	35.8
2012	13,606	51,837	1,931,905	34,157,358	6,526,245,704	39.8	142.0	3.8	37.3

**Table 4b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Year**

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Acetazolamide</b>										
2004	7,786	7,825	10,434	194,295	19,115,751	4,154,034,292	40.7	25.0	1.3	18.6
2005	11,400	11,506	15,247	269,110	21,063,803	5,942,150,500	54.1	23.6	1.3	17.7
2006	13,186	13,287	17,529	325,027	22,741,078	6,260,272,833	58.0	24.6	1.3	18.5
2007	15,518	15,616	20,253	378,846	28,279,216	6,806,535,062	54.9	24.4	1.3	18.7
2008	25,713	25,859	34,770	626,920	49,205,904	11,252,853,317	52.3	24.4	1.4	18.0
2009	29,636	29,881	40,819	761,402	49,254,801	13,921,998,126	60.2	25.7	1.4	18.7
2010	29,445	29,714	40,538	763,716	47,247,258	13,408,901,815	62.3	25.9	1.4	18.8
2011	27,022	27,223	36,706	698,228	46,470,664	13,022,422,069	58.1	25.8	1.4	19.0
2012	14,703	14,716	18,786	353,664	27,828,689	5,104,047,904	52.8	24.1	1.3	18.8
<b>Carbamazepine</b>										
2004	7,627	7,753	19,149	765,275	19,115,751	4,154,034,292	39.9	100.3	2.5	40.0
2005	8,762	8,966	21,489	844,314	21,063,803	5,942,150,500	41.6	96.4	2.5	39.3
2006	8,847	9,042	22,649	900,033	22,741,078	6,260,272,833	38.9	101.7	2.6	39.7
2007	9,334	9,537	22,453	901,152	28,279,216	6,806,535,062	33.0	96.5	2.4	40.1
2008	15,110	15,399	35,932	1,327,915	49,205,904	11,252,853,317	30.7	87.9	2.4	37.0
2009	15,895	16,222	39,083	1,460,675	49,254,801	13,921,998,126	32.3	91.9	2.5	37.4
2010	14,958	15,255	36,800	1,414,617	47,247,258	13,408,901,815	31.7	94.6	2.5	38.4
2011	13,158	13,387	30,833	1,218,448	46,470,664	13,022,422,069	28.3	92.6	2.3	39.5
2012	6,543	6,556	12,397	497,251	27,828,689	5,104,047,904	23.5	76.0	1.9	40.1
<b>Clobazam</b>										
2004	0	0	0	0	19,115,751	4,154,034,292	0.0	---	---	---
2005	0	0	0	0	21,063,803	5,942,150,500	0.0	---	---	---
2006	0	0	0	0	22,741,078	6,260,272,833	0.0	---	---	---
2007	0	0	0	0	28,279,216	6,806,535,062	0.0	---	---	---
2008	0	0	0	0	49,205,904	11,252,853,317	0.0	---	---	---
2009	0	0	0	0	49,254,801	13,921,998,126	0.0	---	---	---
2010	0	0	0	0	47,247,258	13,408,901,815	0.0	---	---	---
2011	0	0	0	0	46,470,664	13,022,422,069	0.0	---	---	---
2012	40	40	121	3,893	27,828,689	5,104,047,904	0.1	97.3	3.0	32.2



**Table 4b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Year**

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b><i>Clonazepam</i></b>										
2004	51,664	52,322	122,923	3,497,364	19,115,751	4,154,034,292	270.3	67.7	2.4	28.5
2005	72,625	74,012	173,934	4,984,868	21,063,803	5,942,150,500	344.8	68.6	2.4	28.7
2006	74,187	75,732	166,942	4,838,116	22,741,078	6,260,272,833	326.2	65.2	2.3	29.0
2007	92,214	94,239	228,780	6,725,973	28,279,216	6,806,535,062	326.1	72.9	2.5	29.4
2008	156,049	158,578	344,241	9,929,806	49,205,904	11,252,853,317	317.1	63.6	2.2	28.8
2009	197,303	201,470	463,792	13,385,401	49,254,801	13,921,998,126	400.6	67.8	2.4	28.9
2010	189,720	193,858	448,987	13,104,407	47,247,258	13,408,901,815	401.5	69.1	2.4	29.2
2011	164,828	168,000	368,576	10,851,256	46,470,664	13,022,422,069	354.7	65.8	2.2	29.4
2012	79,932	80,245	145,973	4,299,191	27,828,689	5,104,047,904	287.2	53.8	1.8	29.5
<b><i>Diazepam</i></b>										
2004	124,478	126,096	189,545	2,970,388	19,115,751	4,154,034,292	651.2	23.9	1.5	15.7
2005	176,341	179,929	262,306	3,796,663	21,063,803	5,942,150,500	837.2	21.5	1.5	14.5
2006	179,732	183,141	256,015	3,559,487	22,741,078	6,260,272,833	790.3	19.8	1.4	13.9
2007	207,411	211,664	317,459	4,988,183	28,279,216	6,806,535,062	733.4	24.0	1.5	15.7
2008	325,718	330,569	465,890	6,709,918	49,205,904	11,252,853,317	661.9	20.6	1.4	14.4
2009	390,609	397,437	561,125	7,715,913	49,254,801	13,921,998,126	793.0	19.8	1.4	13.8
2010	369,860	376,316	532,109	7,287,034	47,247,258	13,408,901,815	782.8	19.7	1.4	13.7
2011	314,599	318,978	438,063	5,905,858	46,470,664	13,022,422,069	677.0	18.8	1.4	13.5
2012	144,701	145,058	183,579	2,319,633	27,828,689	5,104,047,904	520.0	16.0	1.3	12.6
<b><i>Ethosuxamide</i></b>										
2004	193	195	632	22,960	19,115,751	4,154,034,292	1.0	119.0	3.3	36.3
2005	228	229	854	32,393	21,063,803	5,942,150,500	1.1	142.1	3.7	37.9
2006	214	220	766	28,024	22,741,078	6,260,272,833	0.9	131.0	3.6	36.6
2007	256	260	887	30,844	28,279,216	6,806,535,062	0.9	120.5	3.5	34.8
2008	394	399	1,440	47,465	49,205,904	11,252,853,317	0.8	120.5	3.7	33.0
2009	546	553	2,233	75,037	49,254,801	13,921,998,126	1.1	137.4	4.1	33.6
2010	571	581	2,290	79,585	47,247,258	13,408,901,815	1.2	139.4	4.0	34.8
2011	514	517	1,996	66,889	46,470,664	13,022,422,069	1.1	130.1	3.9	33.5
2012	237	237	675	23,583	27,828,689	5,104,047,904	0.9	99.5	2.8	34.9

Table 4b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Year

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Ezogabine</b>										
2004	0	0	0	0	19,115,751	4,154,034,292	0.0	---	---	---
2005	0	0	0	0	21,063,803	5,942,150,500	0.0	---	---	---
2006	0	0	0	0	22,741,078	6,260,272,833	0.0	---	---	---
2007	0	0	0	0	28,279,216	6,806,535,062	0.0	---	---	---
2008	0	0	0	0	49,205,904	11,252,853,317	0.0	---	---	---
2009	0	0	0	0	49,254,801	13,921,998,126	0.0	---	---	---
2010	0	0	0	0	47,247,258	13,408,901,815	0.0	---	---	---
2011	0	0	0	0	46,470,664	13,022,422,069	0.0	---	---	---
2012	1	1	1	30	27,828,689	5,104,047,904	0.0	30.0	1.0	30.0
<b>Felbamate</b>										
2004	12	13	36	1,494	19,115,751	4,154,034,292	0.1	124.5	3.0	41.5
2005	22	22	80	3,372	21,063,803	5,942,150,500	0.1	153.3	3.6	42.2
2006	18	21	63	2,623	22,741,078	6,260,272,833	0.1	145.7	3.5	41.6
2007	28	28	89	3,193	28,279,216	6,806,535,062	0.1	114.0	3.2	35.9
2008	34	35	92	3,719	49,205,904	11,252,853,317	0.1	109.4	2.7	40.4
2009	26	27	80	3,034	49,254,801	13,921,998,126	0.1	116.7	3.1	37.9
2010	29	31	88	3,910	47,247,258	13,408,901,815	0.1	134.8	3.0	44.4
2011	26	26	65	3,132	46,470,664	13,022,422,069	0.1	120.5	2.5	48.2
2012	11	11	17	850	27,828,689	5,104,047,904	0.0	77.3	1.5	50.0
<b>Gabapentin</b>										
2004	65,886	66,501	166,791	5,490,773	19,115,751	4,154,034,292	344.7	83.3	2.5	32.9
2005	88,453	89,621	214,625	7,313,197	21,063,803	5,942,150,500	419.9	82.7	2.4	34.1
2006	93,522	94,708	214,436	7,747,410	22,741,078	6,260,272,833	411.2	82.8	2.3	36.1
2007	126,428	128,210	283,763	10,323,599	28,279,216	6,806,535,062	447.1	81.7	2.2	36.4
2008	267,558	270,804	632,030	21,410,513	49,205,904	11,252,853,317	543.8	80.0	2.4	33.9
2009	332,137	337,174	794,888	27,399,518	49,254,801	13,921,998,126	674.3	82.5	2.4	34.5
2010	339,484	344,847	821,460	28,973,286	47,247,258	13,408,901,815	718.5	85.3	2.4	35.3
2011	339,679	344,665	797,165	29,074,209	46,470,664	13,022,422,069	731.0	85.6	2.3	36.5
2012	187,603	187,993	358,660	13,300,959	27,828,689	5,104,047,904	674.1	70.9	1.9	37.1

**Table 4b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Year**

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b><i>Lacosamide</i></b>										
2004	0	0	0	0	19,115,751	4,154,034,292	0.0	---	---	---
2005	0	0	0	0	21,063,803	5,942,150,500	0.0	---	---	---
2006	0	0	0	0	22,741,078	6,260,272,833	0.0	---	---	---
2007	0	0	0	0	28,279,216	6,806,535,062	0.0	---	---	---
2008	0	0	0	0	49,205,904	11,252,853,317	0.0	---	---	---
2009	166	166	310	9,400	49,254,801	13,921,998,126	0.3	56.6	1.9	30.3
2010	523	526	1,531	46,318	47,247,258	13,408,901,815	1.1	88.1	2.9	30.3
2011	435	436	1,428	43,915	46,470,664	13,022,422,069	0.9	100.7	3.3	30.8
2012	212	212	643	21,114	27,828,689	5,104,047,904	0.8	99.6	3.0	32.8
<b><i>Lamotrigine</i></b>										
2004	8,132	8,177	25,948	872,922	19,115,751	4,154,034,292	42.5	107.3	3.2	33.6
2005	13,833	13,926	48,398	1,618,222	21,063,803	5,942,150,500	65.7	117.0	3.5	33.4
2006	18,337	18,461	62,388	2,161,373	22,741,078	6,260,272,833	80.6	117.9	3.4	34.6
2007	22,915	23,109	78,767	2,717,424	28,279,216	6,806,535,062	81.0	118.6	3.4	34.5
2008	40,213	40,494	135,342	4,448,246	49,205,904	11,252,853,317	81.7	110.6	3.4	32.9
2009	45,495	45,886	159,663	5,351,571	49,254,801	13,921,998,126	92.4	117.6	3.5	33.5
2010	42,458	42,889	147,611	5,076,303	47,247,258	13,408,901,815	89.9	119.6	3.5	34.4
2011	38,768	39,109	127,720	4,438,029	46,470,664	13,022,422,069	83.4	114.5	3.3	34.7
2012	17,320	17,346	45,591	1,620,654	27,828,689	5,104,047,904	62.2	93.6	2.6	35.5
<b><i>Levetiracetam</i></b>										
2004	2,427	2,442	7,257	235,222	19,115,751	4,154,034,292	12.7	96.9	3.0	32.4
2005	3,582	3,618	10,948	362,168	21,063,803	5,942,150,500	17.0	101.1	3.1	33.1
2006	4,876	4,923	15,425	520,954	22,741,078	6,260,272,833	21.4	106.8	3.2	33.8
2007	7,738	7,793	24,285	822,252	28,279,216	6,806,535,062	27.4	106.3	3.1	33.9
2008	17,263	17,372	54,729	1,760,597	49,205,904	11,252,853,317	35.1	102.0	3.2	32.2
2009	23,004	23,194	77,640	2,570,500	49,254,801	13,921,998,126	46.7	111.7	3.4	33.1
2010	23,905	24,123	78,760	2,661,034	47,247,258	13,408,901,815	50.6	111.3	3.3	33.8
2011	24,750	24,946	78,172	2,727,129	46,470,664	13,022,422,069	53.3	110.2	3.2	34.9
2012	13,044	13,061	32,187	1,129,694	27,828,689	5,104,047,904	46.9	86.6	2.5	35.1

**Table 4b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Year**

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Lorazepam</b>										
2004	137,809	139,619	250,489	4,734,363	19,115,751	4,154,034,292	720.9	34.4	1.8	18.9
2005	195,962	200,363	360,751	6,724,619	21,063,803	5,942,150,500	930.3	34.3	1.8	18.6
2006	198,202	202,627	347,534	6,481,208	22,741,078	6,260,272,833	871.6	32.7	1.8	18.6
2007	241,490	247,116	475,482	9,713,466	28,279,216	6,806,535,062	853.9	40.2	2.0	20.4
2008	379,408	386,382	680,278	13,329,435	49,205,904	11,252,853,317	771.1	35.1	1.8	19.6
2009	452,047	462,578	828,258	16,340,427	49,254,801	13,921,998,126	917.8	36.1	1.8	19.7
2010	441,592	452,222	808,758	16,230,110	47,247,258	13,408,901,815	934.6	36.8	1.8	20.1
2011	386,376	394,597	676,549	13,717,571	46,470,664	13,022,422,069	831.4	35.5	1.8	20.3
2012	186,119	186,921	279,156	5,446,317	27,828,689	5,104,047,904	668.8	29.3	1.5	19.5
<b>Mephenytoin</b>										
2004	0	0	0	0	19,115,751	4,154,034,292	0.0	---	---	---
2005	1	1	1	30	21,063,803	5,942,150,500	0.0	30.0	1.0	30.0
2006	0	0	0	0	22,741,078	6,260,272,833	0.0	---	---	---
2007	0	0	0	0	28,279,216	6,806,535,062	0.0	---	---	---
2008	0	0	0	0	49,205,904	11,252,853,317	0.0	---	---	---
2009	0	0	0	0	49,254,801	13,921,998,126	0.0	---	---	---
2010	0	0	0	0	47,247,258	13,408,901,815	0.0	---	---	---
2011	0	0	0	0	46,470,664	13,022,422,069	0.0	---	---	---
2012	0	0	0	0	27,828,689	5,104,047,904	0.0	---	---	---
<b>Oxcarbazepine</b>										
2004	8,828	8,865	28,124	826,329	19,115,751	4,154,034,292	46.2	93.6	3.2	29.4
2005	9,214	9,295	28,783	895,001	21,063,803	5,942,150,500	43.7	97.1	3.1	31.1
2006	8,072	8,146	25,094	805,718	22,741,078	6,260,272,833	35.5	99.8	3.1	32.1
2007	7,950	8,045	25,296	819,987	28,279,216	6,806,535,062	28.1	103.1	3.2	32.4
2008	12,333	12,457	38,969	1,246,186	49,205,904	11,252,853,317	25.1	101.0	3.2	32.0
2009	13,559	13,693	42,420	1,386,667	49,254,801	13,921,998,126	27.5	102.3	3.1	32.7
2010	12,828	12,971	38,534	1,280,416	47,247,258	13,408,901,815	27.2	99.8	3.0	33.2
2011	11,288	11,436	33,165	1,103,174	46,470,664	13,022,422,069	24.3	97.7	2.9	33.3
2012	4,508	4,513	10,261	356,556	27,828,689	5,104,047,904	16.2	79.1	2.3	34.7

Table 4b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Year

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b><i>Phenobarbital</i></b>										
2004	2,042	2,068	5,145	162,313	19,115,751	4,154,034,292	10.7	79.5	2.5	31.5
2005	2,323	2,354	5,103	154,920	21,063,803	5,942,150,500	11.0	66.7	2.2	30.4
2006	2,292	2,318	4,519	137,766	22,741,078	6,260,272,833	10.1	60.1	2.0	30.5
2007	2,603	2,646	6,082	192,419	28,279,216	6,806,535,062	9.2	73.9	2.3	31.6
2008	3,379	3,428	6,969	214,183	49,205,904	11,252,853,317	6.9	63.4	2.1	30.7
2009	3,540	3,566	7,636	234,120	49,254,801	13,921,998,126	7.2	66.1	2.2	30.7
2010	3,096	3,148	6,210	190,508	47,247,258	13,408,901,815	6.6	61.5	2.0	30.7
2011	2,806	2,834	5,398	174,353	46,470,664	13,022,422,069	6.0	62.1	1.9	32.3
2012	1,307	1,308	2,076	64,439	27,828,689	5,104,047,904	4.7	49.3	1.6	31.0
<b><i>Phenytoin, phenytoin sodium</i></b>										
2004	9,177	9,297	28,494	1,024,145	19,115,751	4,154,034,292	48.0	111.6	3.1	35.9
2005	10,300	10,450	30,251	1,079,092	21,063,803	5,942,150,500	48.9	104.8	2.9	35.7
2006	10,197	10,330	30,323	1,100,740	22,741,078	6,260,272,833	44.8	107.9	3.0	36.3
2007	9,862	10,023	26,923	985,460	28,279,216	6,806,535,062	34.9	99.9	2.7	36.6
2008	16,528	16,709	49,282	1,681,628	49,205,904	11,252,853,317	33.6	101.7	3.0	34.1
2009	14,668	14,844	42,256	1,500,641	49,254,801	13,921,998,126	29.8	102.3	2.9	35.5
2010	11,730	11,908	33,305	1,242,472	47,247,258	13,408,901,815	24.8	105.9	2.8	37.3
2011	9,880	10,027	26,879	1,025,905	46,470,664	13,022,422,069	21.3	103.8	2.7	38.2
2012	4,380	4,390	9,494	373,520	27,828,689	5,104,047,904	15.7	85.3	2.2	39.3
<b><i>Pregabalin</i></b>										
2004	0	0	0	0	19,115,751	4,154,034,292	0.0	---	---	---
2005	2,699	2,699	3,975	110,796	21,063,803	5,942,150,500	12.8	41.1	1.5	27.9
2006	18,132	18,224	42,117	1,272,596	22,741,078	6,260,272,833	80.1	69.8	2.3	30.2
2007	29,249	29,453	62,777	1,960,997	28,279,216	6,806,535,062	104.2	66.6	2.1	31.2
2008	93,021	93,795	230,003	7,052,576	49,205,904	11,252,853,317	190.6	75.2	2.5	30.7
2009	53,535	54,084	125,949	4,123,172	49,254,801	13,921,998,126	109.8	76.2	2.3	32.7
2010	45,645	46,176	108,875	3,658,389	47,247,258	13,408,901,815	97.7	79.2	2.4	33.6
2011	37,196	37,557	82,466	2,855,203	46,470,664	13,022,422,069	80.8	76.0	2.2	34.6
2012	18,869	18,909	35,775	1,211,253	27,828,689	5,104,047,904	67.9	64.1	1.9	33.9

**Table 4b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Year**

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Primidone</b>										
2004	1,915	1,935	5,243	212,189	19,115,751	4,154,034,292	10.0	110.8	2.7	40.5
2005	2,365	2,405	6,369	260,214	21,063,803	5,942,150,500	11.2	110.0	2.7	40.9
2006	2,612	2,654	7,020	292,640	22,741,078	6,260,272,833	11.5	112.0	2.7	41.7
2007	3,245	3,314	8,484	355,091	28,279,216	6,806,535,062	11.5	109.4	2.6	41.9
2008	7,807	7,926	21,987	820,996	49,205,904	11,252,853,317	15.9	105.2	2.8	37.3
2009	7,920	8,055	22,461	874,537	49,254,801	13,921,998,126	16.1	110.4	2.8	38.9
2010	7,481	7,633	21,274	867,298	47,247,258	13,408,901,815	15.8	115.9	2.8	40.8
2011	7,353	7,458	20,001	850,155	46,470,664	13,022,422,069	15.8	115.6	2.7	42.5
2012	4,328	4,340	9,104	388,522	27,828,689	5,104,047,904	15.6	89.8	2.1	42.7
<b>Rufinamide</b>										
2004	0	0	0	0	19,115,751	4,154,034,292	0.0	---	---	---
2005	0	0	0	0	21,063,803	5,942,150,500	0.0	---	---	---
2006	0	0	0	0	22,741,078	6,260,272,833	0.0	---	---	---
2007	0	0	0	0	28,279,216	6,806,535,062	0.0	---	---	---
2008	0	0	0	0	49,205,904	11,252,853,317	0.0	---	---	---
2009	40	40	154	4,909	49,254,801	13,921,998,126	0.1	122.7	3.9	31.9
2010	27	28	119	3,588	47,247,258	13,408,901,815	0.1	128.1	4.3	30.2
2011	22	22	83	2,976	46,470,664	13,022,422,069	0.0	135.3	3.8	35.9
2012	9	9	30	916	27,828,689	5,104,047,904	0.0	101.8	3.3	30.5
<b>Tiagabine</b>										
2004	4,412	4,436	10,870	314,525	19,115,751	4,154,034,292	23.1	71.3	2.5	28.9
2005	2,233	2,243	5,113	155,161	21,063,803	5,942,150,500	10.6	69.5	2.3	30.3
2006	785	797	1,842	60,306	22,741,078	6,260,272,833	3.5	76.8	2.3	32.7
2007	502	507	1,137	37,118	28,279,216	6,806,535,062	1.8	73.9	2.3	32.6
2008	665	674	1,470	48,394	49,205,904	11,252,853,317	1.4	72.8	2.2	32.9
2009	506	508	1,181	39,581	49,254,801	13,921,998,126	1.0	78.2	2.3	33.5
2010	296	298	776	26,804	47,247,258	13,408,901,815	0.6	90.6	2.6	34.5
2011	187	190	421	14,819	46,470,664	13,022,422,069	0.4	79.2	2.3	35.2
2012	76	76	138	4,999	27,828,689	5,104,047,904	0.3	65.8	1.8	36.2

**Table 4b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Year**

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b><i>Topiramate</i></b>										
2004	19,717	19,817	50,744	1,654,294	19,115,751	4,154,034,292	103.1	83.9	2.6	32.6
2005	30,054	30,328	85,708	2,792,565	21,063,803	5,942,150,500	142.7	92.9	2.9	32.6
2006	31,445	31,757	87,016	2,969,030	22,741,078	6,260,272,833	138.3	94.4	2.8	34.1
2007	36,018	36,420	98,901	3,444,223	28,279,216	6,806,535,062	127.4	95.6	2.7	34.8
2008	60,135	60,641	149,225	5,010,263	49,205,904	11,252,853,317	122.2	83.3	2.5	33.6
2009	78,746	79,720	212,463	7,190,474	49,254,801	13,921,998,126	159.9	91.3	2.7	33.8
2010	77,618	78,504	207,160	7,127,393	47,247,258	13,408,901,815	164.3	91.8	2.7	34.4
2011	67,134	67,883	166,428	5,849,212	46,470,664	13,022,422,069	144.5	87.1	2.5	35.1
2012	33,319	33,384	67,287	2,387,297	27,828,689	5,104,047,904	119.7	71.6	2.0	35.5
<b><i>Valproic acid</i></b>										
2004	1,114	1,127	2,638	129,249	19,115,751	4,154,034,292	5.8	116.0	2.4	49.0
2005	4,206	4,291	8,265	425,176	21,063,803	5,942,150,500	20.0	101.1	2.0	51.4
2006	2,855	2,885	6,229	262,894	22,741,078	6,260,272,833	12.6	92.1	2.2	42.2
2007	3,033	3,093	6,325	275,418	28,279,216	6,806,535,062	10.7	90.8	2.1	43.5
2008	4,599	4,695	11,725	563,956	49,205,904	11,252,853,317	9.3	122.6	2.5	48.1
2009	3,773	3,852	9,787	427,222	49,254,801	13,921,998,126	7.7	113.2	2.6	43.7
2010	2,592	2,640	6,420	265,991	47,247,258	13,408,901,815	5.5	102.6	2.5	41.4
2011	2,064	2,108	5,052	209,889	46,470,664	13,022,422,069	4.4	101.7	2.4	41.5
2012	905	905	1,719	71,234	27,828,689	5,104,047,904	3.3	78.7	1.9	41.4
<b><i>Vigabatrin</i></b>										
2004	0	0	0	0	19,115,751	4,154,034,292	0.0	---	---	---
2005	0	0	0	0	21,063,803	5,942,150,500	0.0	---	---	---
2006	0	0	0	0	22,741,078	6,260,272,833	0.0	---	---	---
2007	0	0	0	0	28,279,216	6,806,535,062	0.0	---	---	---
2008	0	0	0	0	49,205,904	11,252,853,317	0.0	---	---	---
2009	14	14	29	832	49,254,801	13,921,998,126	0.0	59.4	2.1	28.7
2010	23	23	121	3,868	47,247,258	13,408,901,815	0.0	168.2	5.3	32.0
2011	9	9	25	714	46,470,664	13,022,422,069	0.0	79.3	2.8	28.6
2012	5	5	22	660	27,828,689	5,104,047,904	0.0	132.0	4.4	30.0

**Table 4b. Summary of Incident AED Use in the MSDD between January 1, 2004 and December 31, 2012, by Drug Product and Year**

	Users	New Starts	Dispensings	Total Days Supplied	Eligible Members	Member-Days	New Users/ 100K Eligible Members	Days Supplied/ User	Dispensings/ User	Days Supplied/ Dispensing
<b>Zonisamide</b>										
2004	2,054	2,063	5,779	173,278	19,115,751	4,154,034,292	10.7	84.4	2.8	30.0
2005	2,149	2,167	5,689	178,473	21,063,803	5,942,150,500	10.2	83.0	2.6	31.4
2006	1,884	1,899	5,259	167,483	22,741,078	6,260,272,833	8.3	88.9	2.8	31.8
2007	2,006	2,031	5,440	176,847	28,279,216	6,806,535,062	7.1	88.2	2.7	32.5
2008	3,604	3,634	9,037	294,014	49,205,904	11,252,853,317	7.3	81.6	2.5	32.5
2009	4,361	4,399	11,457	376,570	49,254,801	13,921,998,126	8.9	86.3	2.6	32.9
2010	3,934	3,968	10,680	361,678	47,247,258	13,408,901,815	8.3	91.9	2.7	33.9
2011	3,237	3,262	8,592	296,870	46,470,664	13,022,422,069	7.0	91.7	2.7	34.6
2012	1,405	1,406	2,906	103,580	27,828,689	5,104,047,904	5.0	73.7	2.1	35.6